



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|---|
| (51) International Patent Classification ⁶ : C07D 513/04, A61K 31/519, 31/426, A61P 17/06, 29/00 // (C07D 513/04, 277:00, 239:00) | A1 | (11) International Publication Number: WO 00/09511 (43) International Publication Date: 24 February 2000 (24.02.00) |
| (21) International Application Number: PCT/SE99/01333 (22) International Filing Date: 3 August 1999 (03.08.99) (30) Priority Data: 9802729-5 13 August 1998 (13.08.98) SE (71) Applicant (for all designated States except MG US): ASTRA PHARMACEUTICALS LTD. [GB/GB]; Home Park, Kings Langley, Herts. WD4 8DH (GB). (71) Applicant (for MG only): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): AUSTIN, Rupert [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). BAXTER, Andrew [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). BONNERT, Roger [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). HUNT, Fraser [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). KINCHIN, Elizabeth [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 | | 5RH (GB). WILLIS, Paul [GB/GB]; Astra Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). (74) Agent: ASTRA AKTIEBOLAG; Intellectual Property, Patents, S-151 85 Södertälje (SE). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: NOVEL THIAZOLOPYRIMIDINE COMPOUNDS <div style="text-align: center; margin: 20px 0;"> </div> (57) Abstract <p>The invention provides certain thiazolopyrimidine compounds of general formula (I), processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

NOVEL THIAZOLOPYRIMIDINE COMPOUNDS

The present invention relates to certain thiazolopyrimidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and
5 their use in therapy.

The compound 2,7-diamino-5-methylmercapto-thiazolo[4,5-*d*]pyrimidine is known from J. Amer. Chem. Soc., 73, 4226 – 4227 (1951).

10 Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups
15 exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.


The C-X-C chemokines include several potent chemoattractants and activators of
20 neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).

The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin
25 and the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and MIP-1 β).

Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1,
30 CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug

development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.


In accordance with the present invention, there is therefore provided a compound of
5 general formula



wherein R^1 represents a hydrogen atom, or a group $-NR^3R^4$;

R^3 and R^4 each independently represent a hydrogen atom, or a 4-piperidinyl, C_3 - C_6

10 cycloalkyl or C_1 - C_8 alkyl group, which latter two groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, morpholinyl, C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, tetrahydrofuranyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or
15 indolyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-NR^8COR^9$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_1 - C_6 alkyl and trifluoromethyl groups, or R^3 and R^4 together with the nitrogen atom to which they are attached form a 4- to
20 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from



-NR⁵R⁶, -CONR⁵R⁶, -OR⁷, -COOR¹⁰, -NR⁸COR⁹, and C₁-C₆ alkyl optionally substituted by one or more substituents independently selected from halogen atoms and -NR¹¹R¹² and -OR⁷ groups;

X represents a group -OH or -NR¹³R¹⁴;

5 R¹³ and R¹⁴ each independently represent a hydrogen atom, a 4-piperidinyl group optionally substituted by a C₁-C₄ alkylphenyl substituent group, or a C₃-C₇ carbocyclic, C₁-C₈ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group, which latter four groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and -NR⁵R⁶, -CONR⁵R⁶, -OR⁷, -COOR⁷, -NR⁸COR⁹, -SR¹⁰,
10 -SO₂R¹⁰, -SO₂NR⁵R⁶, -NR⁸SO₂R⁹, morpholinyl, C₁-C₄ alkyl, C₃-C₆ cycloalkyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, -NR⁵R⁶, -CONR⁵R⁶, -OR⁷, -NR⁸COR⁹, -SO₂NR⁵R⁶, NR⁸SO₂R⁹, C₁-C₆ alkyl and
15 trifluoromethyl groups,
or R¹³ and R¹⁴ together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from -NR⁵R⁶, -CONR⁵R⁶, -OR⁷, -COOR⁷, -NR⁸COR⁹, and C₁-C₆ alkyl optionally substituted by one
20 or more substituents independently selected from halogen atoms and phenyl, -NR¹¹R¹² and -OR⁷ groups;

R² represents a C₁-C₆ alkyl or C₂-C₆ alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group may itself be optionally substituted by one or more substituents independently selected from halogen atoms and nitro,

25 C₁-C₆ alkyl, trifluoromethyl, -OR⁷, -C(O)R⁷, -SR¹⁰, -NR¹⁵R¹⁶ and phenyl groups;

R⁵ and R⁶ each independently represent a hydrogen atom or a C₁-C₆ alkyl or phenyl group, each of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, -OR¹⁷ and -NR¹⁵R¹⁶, or
R⁵ and R⁶ together with the nitrogen atom to which they are attached form a 4- to

30 7-membered saturated heterocyclic ring system optionally comprising a further heteroatom

selected from oxygen and nitrogen atoms, which ring system may be optionally substituted by one or more substituent groups independently selected from phenyl, $-OR^{17}$, $-COOR^{17}$, $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SONR^{15}R^{16}$, and C_1 - C_6 alkyl optionally substituted by one or more substituents independently selected from halogen atoms and $-NR^{15}R^{16}$ and $-OR^{17}$ groups;

5 R^7 and R^9 each independently represent a hydrogen atom or a C_1 - C_6 , particularly C_1 - C_4 , alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) or phenyl group, each of which may be optionally substituted by one or more (e.g. one, two, three or four) substituent groups independently selected from halogen atoms (e.g. fluorine, chlorine,

10 bromine or iodine), phenyl, $-OR^{17}$ and $-NR^{15}R^{16}$; and each of R^8 , R^{10} , R^{11} , R^{12} , R^{15} , R^{16} and R^{17} independently represents a hydrogen atom or a C_1 - C_6 , particularly C_1 - C_4 , alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) or phenyl group; with the proviso that when R^1 and X both represent $-NH_2$, then R^2 does not represent a methyl group;

15 or a pharmaceutically acceptable salt or solvate thereof.

In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear or branched. Where a substituent in an alkenyl group is a phenoxy group, the phenoxy group is not

20 attached to an unsaturated carbon atom. A carbocyclic group is a saturated hydrocarbyl group that may be monocyclic or polycyclic (e.g. bicyclic). Similarly, a saturated heterocyclic ring system may be monocyclic or polycyclic (e.g. bicyclic).


In formula (I) above, the group R^1 represents a hydrogen atom, or a group $-NR^3R^4$.

25 Particularly advantageous compounds of formula (I) are those in which R^1 represents a group $-NR^3R^4$.

Preferably, R^3 and R^4 each independently represent a hydrogen atom, or a 4-piperidinyl, C_3 - C_6 cycloalkyl (i.e. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) or C_1 - C_8 ,

30 particularly C_1 - C_6 , alkyl group (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl,

t-butyl, pentyl, hexyl, heptyl or octyl), which latter two groups may be optionally substituted by one, two, three or four substituent groups independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and $-\text{NR}^5\text{R}^6$, $-\text{CONR}^5\text{R}^6$, $-\text{OR}^7$, $-\text{COOR}^7$, $-\text{NR}^8\text{COR}^9$, $-\text{SR}^{10}$, $-\text{SO}_2\text{R}^{10}$, $-\text{SO}_2\text{NR}^5\text{R}^6$, $-\text{NR}^8\text{SO}_2\text{R}^9$, morpholinyl, C_1 - C_4 alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl or t-butyl), C_3 - C_6 cycloalkyl (i.e. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), tetrahydrofuranyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one, two, three or four substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and cyano, nitro, $-\text{NR}^5\text{R}^6$, $-\text{CONR}^5\text{R}^6$, $-\text{OR}^7$, $-\text{NR}^8\text{COR}^9$, $-\text{SO}_2\text{NR}^5\text{R}^6$, $-\text{NR}^8\text{SO}_2\text{R}^9$, C_1 - C_6 , particularly C_1 - C_4 , alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) and trifluoromethyl groups, or R^3 and R^4 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one, two or three substituent groups independently selected from



$-\text{NR}^5\text{R}^6$, $-\text{CONR}^5\text{R}^6$, $-\text{OR}^7$, $-\text{COOR}^{10}$, $-\text{NR}^8\text{COR}^9$, and C_1 - C_6 , particularly C_1 - C_4 , alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) optionally substituted by one, two or three substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and $-\text{NR}^{11}\text{R}^{12}$ and $-\text{OR}^7$ groups.

Particularly advantageous compounds of formula (I) are those in which R^3 and R^4 each independently represent a hydrogen atom, or a C_1 - C_6 alkyl group substituted by a $-\text{CONR}^5\text{R}^6$ or imidazolyl (e.g. 1*H*-imidazol-4-yl) group.

Preferably, R^2 represents a C_1 - C_6 alkyl or C_2 - C_6 alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group may itself be optionally

substituted by one, two, three or four substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and nitro, C₁-C₆, particularly C₁-C₄, alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl), trifluoromethyl, -OR⁷, -C(O)R⁷, -SR¹⁰, -NR¹⁵R¹⁶ and phenyl groups.

5

Particularly advantageous compounds of formula (I) are those in which R² represents a C₁-C₆ alkyl group optionally substituted by a phenyl, halophenyl (e.g. 2,3-difluorophenyl) or -OR⁷ (e.g. phenoxy) group.

- 10 Preferably, R⁵ and R⁶ each independently represent a hydrogen atom or a C₁-C₆, particularly C₁-C₄, alkyl or phenyl group, each of which may be optionally substituted by one, two, three or four substituent groups independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine), phenyl, -OR¹⁷ and -NR¹⁵R¹⁶, or R⁵ and R⁶ together with the nitrogen atom to which they are attached form a 4- to
- 15 7-membered saturated heterocyclic ring system optionally comprising a further heteroatom selected from oxygen and nitrogen atoms (e.g. one or two oxygen and/or nitrogen atoms), which ring system may be optionally substituted by one, two or three substituent groups independently selected from phenyl, -OR¹⁷, -COOR¹⁷, -NR¹⁵R¹⁶, -CONR¹⁵R¹⁶, -NR¹⁵COR¹⁶, -SONR¹⁵R¹⁶, and C₁-C₆, particularly C₁-C₄, alkyl (e.g. methyl, ethyl,
- 20 propyl, butyl, pentyl or hexyl) optionally substituted by one, two or three substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and -NR¹⁵R¹⁶ and -OR¹⁷ groups.

- Preferably, R¹³ and R¹⁴ each independently represent a hydrogen atom, a 4-piperidinyl
- 25 group optionally substituted by a C₁-C₄ alkylphenyl substituent group, or a C₃-C₇ carbocyclic, C₁-C₈, particularly C₁-C₆, alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl or octyl), C₂-C₆ alkenyl (ethenyl, propenyl, butenyl, pentenyl or hexenyl) or C₂-C₆ alkynyl (ethynyl, propynyl, butynyl, pentynyl or hexynyl) group, which latter four groups may be optionally substituted by one, two, three or four
- 30 substituent groups independently selected from halogen atoms (e.g. fluorine, chlorine,

bromine or iodine) and $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, morpholinyl, C_1 - C_4 alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl or t-butyl), C_3 - C_6 cycloalkyl (i.e. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one, two, three or four substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and cyano, nitro, $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-NR^8COR^9$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_1 - C_6 , particularly C_1 - C_4 , alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) and trifluoromethyl groups, or R^{13} and R^{14} together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one, two or three substituent groups independently selected from $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-COOR^7$, $-NR^8COR^9$, and C_1 - C_6 , particularly C_1 - C_4 , alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) optionally substituted by one, two or three substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and phenyl, $-NR^{11}R^{12}$ and $-OR^7$ groups;

Particularly advantageous compounds of formula (I) are those in which one of R^{13} and R^{14} represents a hydrogen atom and the other of R^{13} and R^{14} represents a C_1 - C_6 alkyl group substituted by an $-OR^7$ group, e.g. $-CH(CH_2CH_3)CH_2OH$, $-C(CH_3)_2CH_2OH$ or $CH(CH_2CH(CH_3)_2)CH_2OH$.

Particularly preferred compounds of the invention include:

(2*R*)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
 (2*S*)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
 2-Amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 5-[[3-Phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 (±)-2-[[2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
 2-[[2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethanol,

- 5-(Pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-[[3-(Dimethylamino)propyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
5 2-[[2-(Diethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-[[2-(Dimethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-[(3-Hydroxypropyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-[[2-(Acetylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
(±)-2-[(2,3-Dihydroxypropyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
10 2-[[2-(4-Morpholinyl)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-[(2-Methoxyethyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-[(1-Methylethyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-(Cyclopropylamino)-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
(±)-2-[(2-Hydroxypropyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
15 2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-[(2-Hydroxy-2-methylpropyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-[(2-Hydroxyethyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
(2*S*,3*R*)-3-Hydroxy-2-[(7-oxo-5-(pentylthio)-4*H*-thiazolo[4,5-*d*]pyrimidin-2-yl)-
amino)butanamide,
20 *N*⁷-[3-(Dimethylamino)propyl]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
*N*⁷-[2-(Diethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
*N*⁷-[2-(Dimethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
3-[(2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl)amino]-1-propanol,
*N*⁷-Cyclohexyl-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
25 (±)-3-[(2-Amino-5-((phenylmethyl)thio)thiazolo[4,5-*d*]pyrimidin-7-yl)amino]-1,2-
propanediol,
*N*⁷-(2-Methoxyethyl)-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
5-(Pentylthio)-*N*⁷-propylthiazolo[4,5-*d*]pyrimidine-2,7-diamine,
*N*⁷-Cyclopentyl-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
30 *N*⁷-Cyclopropyl-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,

- N*⁷-(2-Methylpropyl)-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
(±)-1-[(2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl)amino]-2-propanol,
(exo)-*N*⁷-Bicyclo[2.2.1]hept-2-yl-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
2-[2-[[2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethoxy]ethanol,
5 (±)-*N*⁷-(2-Methylbutyl)-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
1-[[2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-2-propanol,
*N*⁷-[(2-Aminophenyl)methyl]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
2-Amino-5-[(2-phenoxyethyl)thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
(*E*)-2-Amino-5-[(3-phenyl-2-propenyl)thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
10 2-Amino-5-[[3-[2,4-bis(1,1-dimethylethyl)phenoxy]propyl]thio]thiazolo[4,5-*d*]pyrimidin-
7(4*H*)-one,
2-Amino-5-[[[(4-trifluoromethyl)phenyl]methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-Amino-5-[[[(3,5-dichlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-Amino-5-[[[(2,4-dichlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
15 2-Amino-5-[[[(3,4-dichlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-Amino-5-[[[(3,5-dibromophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-Amino-5-[[[(2-nitrophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-Amino-5-[[[(2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-Amino-5-[[[(2-iodophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
20 2-Amino-5-[[[(3-chlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-Amino-5-[[[(2-chlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-Amino-5-[[[(4-chloro-2-nitrophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-Amino-5-[[[(3-chloro-4-methoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-Amino-5-[[[(2,3-dichlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
25 2-Amino-5-[[[(3,5-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-Amino-5-[[[(2,4-bis(trifluoromethyl)phenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-
one,
2-Amino-5-[[[(2-bromophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
2-Amino-5-[[[(2,3,4-trifluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
30 2-Amino-5-[[[(3-bromophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,

2-Amino-5-[[2-fluoro-3-methylphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2,2-dimethyl-1-
propanol,

(±)-α-[[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-
5 yl]amino]methyl]benzenemethanol,

(*R*)-β-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-
yl]amino]benzenepropanol,

2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethanol,

(2*R*)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]4-
10 methylpentanol,

(±)-1-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol,

(±)-β-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-
chlorobenzenepropanol,

(±)-3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,2-
15 propanediol,

2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]propylamino]ethanol,

(±)-1-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-pyrrolidinol,

(±)-1-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinol,

1-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-piperidinol,

20 3-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2,2-
dimethyl-1-propanol,

(±)-2-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-
1-butanol,

(±)-α-[[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-
25 amino]methyl]benzenemethanol,

4-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-
butanol,

6-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-
hexanol,

- 4-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-amino]cyclohexanol,
- (*R*)-β-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-amino]benzenepropanol,
- 5 (±)-2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-amino]ethanol,
- (2*R*)-2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-amino]-4-methylpentanol,
- 10 (±)-1-Amino-3-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol,
- (±)-1-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol,
- 15 2-[[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]methyl]-2-ethyl-1,3-propanediol,
- (±)-β-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-chlorobenzenepropanol,
- (±)-3-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,2-propanediol,
- 20 2-[[2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethyl]amino]ethanol,
- 3-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 25 (±)-α-[[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]methyl]-3,4-dichlorobenzenepropanol,
- 1-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-2-propanol,
- 2-[[2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethoxy]ethanol,
- 30

- 5-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol,
- (2*S*)-2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-(methylthio)-1-butanol,
- 5 2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]butylamino]ethanol,
- 2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]propylamino]ethanol,
- 2,2'-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]imino]bisethanol,
- 10 2-[[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-(2-hydroxyethyl)amino]methyl]phenol,
- 3-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-(2-hydroxyethyl)amino]-1-propanol,
- 15 (±)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-pyrrolidinol,
- (*trans*)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-hydroxy-*L*-proline phenylmethyl ester,
- (±)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinemethanol,
- 20 (±)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinol,
- (2*S*)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-2-pyrrolidinemethanol,
- 25 1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-piperidinol,
- (2*R*)-2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- (2*S*)-2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- 30

(2*R*)-2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,

2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,3-propanediol,

5 2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

10 1-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-2-propanol,

5-[[[(2,3-Difluorophenyl)methyl]thio]-*N*⁷-(2-fluoroethyl)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,

(1*R-trans*) 2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-cyclopentanol,

15 (1*S-trans*) 2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-cyclopentanol,

2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

20 2-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

2-[[2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(phenylmethyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

5-[[[(2,3-Difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,

25 (±)-2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,

(1*S*,2*S*)-2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-cyclohexanol,

(±)-2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

- 2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-ethanol,
- (2*R*)-2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
- 5 (±)-1-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol,
- 2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1,3-propanediol,
- 1-[[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]methyl]-cyclohexanol,
- 10 (2*R*)-2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- 2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-(2-aminoethyl)amino]-1-ethanol,
- 15 2-[2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethoxy]-1-ethanol,
- (αS)- α -[(1*R*)-1-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]methylamino]ethyl]-benzenemethanol,
- 1-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-
- 20 piperidinol,
- 5-[[[(2,3-Difluorophenyl)methyl]thio]-*N*⁷-ethyl-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
- 5-[[[(2,3-Difluorophenyl)methyl]thio]-*N*⁷-(2-propenyl)-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
- (1*S*,2*S*)-2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-
- 25 yl]amino]-1-phenyl-1,3-propanediol,
- 2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,3-propanediol,
- 2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-ethanol,

- (±)-5-[[[(2,3-Difluorophenyl)methyl]thio]-*N*⁷-(2-methoxy-1-methylethyl)-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
*N*⁷-Cyclopropyl-5-[[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
- 5 (±)-2-[[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
4-[[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
5-[[[(2,3-Difluorophenyl)methyl]thio]-*N*⁷-[2-(1*H*-imidazol-4-yl)ethyl]-thiazolo[4,5-
10 *d*]pyrimidine-2,7-diamine,
(±)-*N*-[5-[[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-*d*]pyrimidin-2-yl]-serine, methyl ester,
2-[[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(1-methylethyl)amino]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 15 2-[[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-(ethylamino)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(1*H*-indol-3-yl)ethyl]amino]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-
20 *d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(1,2-diphenylethyl)amino]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(2,2,2-trifluoroethyl)amino]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 25 2-[[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[[[3,4,5-trimethoxyphenyl)methyl]amino]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(1,1-dimethylethyl)amino]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

- 2-[[5-[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-[[5-[(2,3-Difluorophenyl)methyl]thio]-2-[(4-methylcyclohexyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 5 2-[[5-[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-acetamide,
- 2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-[[5-[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 10 2-[[2-(Cyclopropylamino)-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- (±)-2-[[5-[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-pentanol,
- 15 2-[[5-[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-hydroxyethoxy)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- N*-[5-[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-*d*]pyrimidin-2-yl]-DL-serine, methyl ester,
- 5-[(2,3-Difluorophenyl)methyl]thio]-2-[(1-methylethyl)amino]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 20 5-[[2-(2,3-Difluorophenyl)methyl]thio]-2-[[2-(1*H*-indol-3-yl)ethyl]amino]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-[[5-[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-acetamide,
- 25 2-[[2-(4-Aminophenyl)ethyl]amino]-5-[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 5-[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 5-[[2-(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-hydroxyethoxy)ethyl]amino]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 30

2-[[2-(Cyclohexylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

2-[[2-[(1,1-Dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

5 *N*-[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]-DL-alanine, methyl ester,

4-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-cyclohexanol,

2-Methyl-2-[[2-[(4-phenylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

2-Methyl-2-[[2-[(1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

15 2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

N-[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]-L-valine, ethyl ester,

(2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-4-methyl-pentanamide,

2-Methyl-2-[[2-[(2-phenylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

2-[[2-[[4-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

25 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

2-[[2-[(2-Fluoroethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

2-Methyl-2-[[2-[[3-nitrophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

- (αR)- α -[(1*S*)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-benzenemethanol,
2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[(3,4,5-trimethoxyphenyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
5 2-Methyl-2-[[2-[(1*R*-trans)-(2-phenylcyclopropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
2-[[2-[[2-(1*H*-Indol-3-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[2-[(1,1-Dimethylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
10 (±)-2-Methyl-2-[[2-[(1-methylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
(±)-2-Methyl-2-[[2-[(1-methylhexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
15 2-[[2-[[2-(2-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1,3-propanediol,
2-[[2-[[2-(Ethylthio)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
20 (2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-3,3-dimethyl-1-butanol,
(αS)- α -[(1*R*)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-2-methoxyethyl]-
25 benzenemethanol,
2-[[2-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[2-[[[3-Fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

- (±)-2-Methyl-2-[[2-[(1-methylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
2-[[2-[[4-Methoxyphenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
5 2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[2-[(2-(1*H*-Imidazol-4-yl)ethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[2-[(Diphenylmethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
10 2-[[2-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-butanol,
2-[[2-[(2,2-Diethoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
15 4-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-butanol,
(1*S*,2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-cyclohexanol,
(±)-2-[[2-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
20 2-[[2-[(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
(±)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-pentanol,
25 2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-acetamide,
(±)-2-[[2-[[1-(4-Fluorophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-propanol,
(1*R*,2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-cyclohexanol,
30

- (αS)- α -[(1*R*)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-benzenemethanol,
 (\pm)-2-[[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
 5 (2*R*)-4-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol,
N-[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-L-serine, ethyl ester,
 (\pm)-2-[[5-[(Phenylmethyl)thio]-2-[[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-
 10 *d*]pyrimidin-7-yl]amino]-1-butanol,
 (\pm)-2-[[5-[(Phenylmethyl)thio]-2-[[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-1-propanol,
 (2*R*)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-1-pentanol,
 15 *N*-[5-[(Phenylmethyl)thio]-2-[[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-
d]pyrimidin-7-yl]-L-serine, ethyl ester,
 (\pm)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-1-propanol,
 (\pm)-4-[2-[[7-[[1-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
 20 *d*]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,
 (\pm)-4-[2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,
 4-[2-[[7-[[1-(Hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,
 25 (\pm)-4-[2-[[7-[(2-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,
*N*⁷-Ethyl-*N*²-[2-(1*H*-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidine-
 2,7-diamine,
*N*²-[2-(1*H*-Imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]-*N*⁷-(3-pyridinylmethyl)-
 30 thiazolo[4,5-*d*]pyrimidine-2,7-diamine,

- (±)-2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- (±)-2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 5 (2*R*)-2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
- (±)-1-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol,
- 5-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-
- 10 7-yl]amino]-1-pentanol,
- 1-[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-(phenylmethyl)-4-piperidinol,
- (±)-1-[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinecarboxamide,
- 15 2-[Ethyl[2-[[2-(1*H*-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-ethanol,
- N*²-[2-(1*H*-Imidazol-4-yl)ethyl]-*N*⁷,*N*⁷-dimethyl-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
- N*⁷-[2-(Diethylamino)ethyl]-*N*⁷-ethyl-*N*²-[2-(1*H*-imidazol-4-yl)ethyl]-5-
- 20 [(phenylmethyl)thio]-thiazolo[4,5-*d*]pyriraidine-2,7-diamine,
- N*²-(2-Phenoxyethyl)-5-[(phenylmethyl)thio]-*N*⁷-(3-pyridinylmethyl)-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
- N*²-(2-Phenoxyethyl)-*N*⁷-[1-(phenylmethyl)-4-piperidinyl]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
- 25 2-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- (±)-2-[[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- (±)-4-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol,
- 30

- 1-[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-(phenylmethyl)-4-piperidinol,
2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
5 2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
(2*R*)-2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
N-[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-L-serine,
10 ethyl ester,
(2*R*)-2-[[2-[[1-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
N-[2-[[1-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-L-serine, ethyl ester,
15 (±)-2-[[7-[Cyclohexyl(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-pentanol,
2-[2-[[7-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethoxy]-1-ethanol,
2-[2-[[7-[(1-Methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethoxy]-1-ethanol,
20 (±)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
25 (2*R*)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
2-[Cyclohexyl-2-[[2-(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-ethanol,
(±)-2-[[5-[(Phenylmethyl)thio]-2-(4-piperidinylamino)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
30

- (±)-*N*-[2-[[7-[[1-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-acetamide,
- (±)-*N*-[2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-acetamide,
- 5 *N*-[2-[[7-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-acetamide,
- N*-[2-[[7-[(1*R*)-1-(Hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-acetamide,
- N*⁷-(2-Methoxyethyl)-5-[(phenylmethyl)thio]-*N*²-[2-(2-thienyl)ethyl]thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
- 10 *N*⁷-(2-Ethoxyethyl)-5-[(phenylmethyl)thio]-*N*²-[2-(2-thienyl)ethyl]thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
- N*⁷-(2,2-Dimethylpropyl)-5-[(phenylmethyl)thio]-*N*²-[2-(2-thienyl)ethyl]thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
- 15 (2*R*)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol,
- (±)-1-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol,
- (±)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- 20 (±)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- (2*R*)-2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
- 25 (±)-*N,N*-Diethyl-1-[2-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinecarboxamide,
- (2*R*)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
- (±)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- 30

(±)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-acetamide,

5 4-[1-[7-[(4-Methylcyclohexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]-3-azetidiny]-1-piperazinesulfonamide,

3-[[2-[[2-(4-Morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

2-Methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

10 (±)-2-[[2-[[2-(4-Morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

(2*R*)-4-Methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol,

15 2-[[2-(3,4-Dihydroxyphenyl)ethyl]amino]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,


(±)-2-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,

and their pharmaceutically acceptable salts and solvates.

20


According to the invention there is also provided a process for the preparation of a compound of formula (I) which comprises:

(a) when X represents -OH and R¹ is NH₂, heating a compound of general formula




25 wherein R² is as defined in formula (I); or

(b) when X represents -OH and R¹ is NH₂, reacting a compound of formula




with a compound of general formula (IV), $R^2 - L^1$, wherein L^1 represents a leaving group such as a halogen atom (e.g. chlorine) and R^2 is as defined in formula (I); or

- (c) when X represents $-OH$ or $-NR^{13}R^{14}$ and R^1 is a hydrogen atom, reacting a
 5 corresponding compound of formula (I) in which R^1 is NH_2 , with a diazotizing agent; or
 (d) when X represents $-OH$ and R^1 is a group $-NR^3R^4$, reacting a compound of general formula




wherein L^2 represents a leaving group such as a halogen atom (e.g. bromine) and R^2 is as
 10 defined in formula (I), with a compound of general formula (VI), R^3R^4NH , wherein R^3 and R^4 are as defined in formula (I); or

- (e) when X represents $-NR^{13}R^{14}$ and R^1 represents $-NR^3R^4$, reacting a compound of general formula



15 wherein L^3 represents a leaving group such as a halogen atom (e.g. chlorine) and R^2 , R^3 and R^4 are as defined in formula (I), with a compound of general formula (VIII), $NHR^{13}R^{14}$, wherein R^{13} and R^{14} are as defined in formula (I); or

- (f) when X represents $-NR^{13}R^{14}$ and R^1 represents $-NR^3R^4$, reacting a compound of general formula



wherein L^4 is a leaving group (e.g. bromine), L^5 is a leaving group (e.g. chlorine) and R^2 is as defined in formula (I), initially with a compound of formula (VI) as defined in (d) above followed by reaction with a compound of formula (VIII) as defined in (e) above;

and optionally after (a), (b), (c), (d), (e) or (f) forming a pharmaceutically acceptable salt or solvate of the compound of formula (I).

Process (a) is conveniently carried out in the presence of a solvent or solvent mixture such as dimethylformamide/water at a temperature in the range from e.g. 50 to 150°C.

Process (b) is conveniently carried out in an organic solvent such as tetrahydrofuran or dimethyl sulfoxide/dimethylformamide mixture, optionally in the presence of a base such as potassium *tert*-butoxide or diisopropylamide.


Process (c) is conveniently carried out in an organic solvent such as tetrahydrofuran. Examples of suitable diazotizing agents to use include *tert*-butyl nitrite.

Process (d) is conveniently carried out in an organic solvent such as tetrahydrofuran, e.g. at a temperature of 50°C for 5 hours.

Process (e) is conveniently carried out in an organic solvent such as tetrahydrofuran with heating for a period in the range from 1 day to 3 weeks.


Process (f) is conveniently carried out in an organic solvent such as tetrahydrofuran or N-methylpyrrolidine at a temperature between 0° and 130°C, with a reaction time of 1 hour to 3 weeks.

Compounds of formula (II) may be readily prepared by reacting a compound of general formula



- 5 wherein R^2 is as defined above, with potassium thiocyanate and bromine in dimethylformamide/pyridine.

Compounds of formula (X) are suitably prepared by reacting a compound of formula



- 10 with a compound of formula (IV) as defined above.

Compounds of formula (V) may be prepared by reacting a compound of formula (I) in which R^1 is NH_2 , with a diazotizing agent and a halogenating agent. The reaction is conveniently carried out in an organic solvent such as acetonitrile in the presence of a
15 diazotizing agent such as *tert*-butyl nitrite and a halogenating agent such as a trimethylsilyl halide.

Compounds of formula (VII) in which L^3 is a chlorine atom may be prepared by reacting a compound of formula (I) in which X is -OH with phosphorus oxychloride in
20 dimethylaniline under reflux conditions.

Compounds of formula (IX) in which L^4 represents a bromine atom and L^5 represents a chlorine atom may be prepared by reacting a compound of formula (I) in which X is -OH and R^1 is NH_2 with phosphorus oxychloride in dimethylaniline under reflux conditions,
25 followed by reaction with *tert*-butyl nitrite and bromoform.

Compounds of formulae (III), (IV), (VI), (VIII) and (XI) are either commercially available, are well known in the literature or may be prepared easily using known techniques.

5 The compounds of formulae (V), (VII) and (IX) are novel intermediates and therefore form a further aspect of the present invention. In formula (V), L^2 is preferably a bromine atom. In formula (VII), R^3 and R^4 preferably both represent a hydrogen atom. In formula (IX), L^3 is preferably a bromine atom and L^4 is preferably a chlorine atom.

10 It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups.

15


The protection and deprotection of functional groups is fully described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 2nd edition, T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1991).

20


The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate.

25

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention, for example tautomers of
30 general formula




wherein R¹ and R² are as defined in formula (I), or of general formula





5 wherein R¹ and R² are as defined in formula (I).


Similarly, it will be understood that in the above processes tautomeric forms of the compounds of formulae (II), (III), (IX) and (X) may also be used, for example,



10



and



The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CXCR2) activity, and may be used in the treatment
5 (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines. Examples of such conditions/diseases include:

- 10 (1) **(the respiratory tract)** obstructive airways diseases including chronic obstructive pulmonary disease (COPD) such as irreversible COPD; asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis
15 including croupous, fibrinous and pseudomembranous rhinitis and serofolous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
- 20 (2) **(bone and joints)** rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis;
- 25 (3) **(skin)** psoriasis, atopic dermatitis, contact dermatitis and other eczematous dermatides, seborrhectic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis;

(4) (**gastrointestinal tract**) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;

5

(5) (**other tissues and systemic disease**) multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, Sezary syndrome and idiopathic thrombocytopenia purpura;

10

(6) (**allograft rejection**) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease;

15

(7) cancers, especially non-small cell lung cancer (NSCLC) and squamous sarcoma;

(8) diseases in which angiogenesis is associated with raised CXCR2 chemokine levels (e.g. NSCLC); and

20

(9) cystic fibrosis, stroke, re-perfusion injury in the heart, brain, peripheral limbs and sepsis.

Thus, the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

25

In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

30

In a still further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.

5

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

10 The invention still further provides a method of treating a chemokine mediated disease wherein the chemokine binds to a CXCR2 receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

15 The invention also provides a method of treating an inflammatory disease, especially psoriasis, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

20 For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof
25 may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w,


still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

5 The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

10 The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.

15 The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.

20 The invention will now be further illustrated by reference to the following examples. In the examples the Nuclear Magnetic Resonance (NMR) spectra were measured on a Varian Unity Inova 300 or 400 MHz spectrometer and the Mass Spectrometry (MS) spectra measured on a Finnigan Mat SSQ7000 or Micromass Platform spectrometer. Where necessary, the reactions were performed under an inert atmosphere of either nitrogen or
25 argon. Chromatography was generally performed using Matrex Silica 60[®] (35-70 micron) or Prolabo Silica gel 60[®] (35-70 micron) suitable for flash silica gel chromatography. High pressure liquid chromatography purification was performed using either a Waters Micromass LCZ with a Waters 600 pump controller, Waters 2487 detector and Gilson FC024 fraction collector or a Waters Delta Prep 4000. The abbreviations m.p. and DMSO
30 used in the examples stand for melting point and dimethyl sulphoxide respectively.

Example 1**(2*R*)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol****(a) 7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-amine**

2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one (0.89g) (prepared as described in Example 9), phosphorus oxychloride (12mL) and *N,N*-dimethylaniline (1.2mL) were heated at reflux for 2 hours. The cooled reaction mixture was poured onto ice and water and stirred for 2 hours. Chromatography on silica eluting with methanol/dichloromethane mixtures gave the sub-title chloride.

m.p. 217-218.5°C

MS: APCI(+ve) 309/11 (M+1)

¹H NMR: δ (DMSO) 4.38 (s,2H), 7.20-7.48 (m,5H) and 8.95 (br s,2H).

(b) (2*R*)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol

The chloro compound from step (a) (0.12g) in tetrahydrofuran (3 mL) was treated with (*R*)-2-amino-1-butanol (0.56g) and the reaction mixture was heated at reflux for 5 days. Dichloromethane and dilute hydrochloric acid were added. The resulting solid was filtered off, washed with water and ether to give the title compound which was obtained containing 0.23 moles of hydrogen chloride and 0.93 moles of water. Yield 0.045g.


m.p. 118-121°C

MS: APCI(+ve) 362 (M+1)

¹H NMR: δ (DMSO) 0.83 (t,3H), 1.45 (m,2H), 1.65 (m,2H), 3.39 (m,2H), 4.31 (q,2H), 4.65 (t,1H), 6.91 (d,1H), 7.17-7.44 (m,5H) and 8.00 (s,2H).

5 Example 2

(S)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-butanol



Prepared by the method of Example 1(b) from the chloro compound of Example 1(a) and
10 (S)-2-amino-1-butanol. Obtained as a solid containing 0.7 moles of hydrogen chloride.


mp 204-208°C

MS: APCI(+ve) 362 (M+1)

¹H NMR: δ (DMSO) 0.82 (t,3H), 1.37-1.74 (m,2H), 3.36-3.52 (m,2H), 4.10 (br s,1H),
15 4.41 (q,2H), 7.20-7.46 (m,5H), 7.63 (br s,1H) and 8.42 (s,2H).

Example 3

2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4H)-one



20 a) 2-Amino-5-mercapto-thiazolo[4,5-d]pyrimidin-7(4H)-one

Aluminium tribromide (1M in CH₂Br₂, 15.2ml) was added to a solution of the product of Example 9 (2.0g) in toluene (25ml) and the reaction mixture heated at 60°C for 6 hours.

On cooling to room temperature, water (40ml) was added and the resulting solid isolated by filtration then triturated with hot ethanol to afford the sub-title compound (0.8g).

MS: (APCI) 201 ($M+H^+$, 100%)

5

b) 2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one

Potassium t-butoxide solution (0.45mL of 1M in tetrahydrofuran) was added to a stirred solution of the product of step a) (0.09g) and 2,3-difluorobenzyl bromide in dimethyl sulphoxide (2mL). After stirring for 3 days, the reaction mixture was poured onto water.

10 The title compound was obtained. Yield 0.065g.

m.p. 310-313°C


MS: APCI(+ve) 327 ($M+1$)

1H NMR: δ (DMSO) 4.48 (s,2H), 7.18-7.45 (m,3H), 8.20 (s,2H) and 12.62 (s,1H).

15

Example 4

5-[[[(3-Phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one




2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one (0.3g)

20 (product of Example 5) was added over 90 minutes to a solution of t-butyl nitrite (0.17mL) in tetrahydrofuran (3mL) at 65°C. After a further 3.5 hours at 65°C, the solvent was evaporated and the residue chromatographed on silica eluting with methanol/dichloromethane mixtures to give the title compound. Yield 0.071g.

25 m.p. 197-198°C

MS: APCI(+ve) 368 ($M+1$)

1H NMR: δ (DMSO) 4.49 (s,2H), 6.86-7.38 (m,9H), 9.58 (s,1H) and 13.11 (s,1H).

Example 5**2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**


5 Prepared by the method of Example 3 using 3-phenoxybenzyl chloride.

m.p. 266-269°C

MS: APCI(+ve) 383 (M+1)

¹H NMR: δ (DMSO) 4.40 (s,2H), 6.81-7.41 (m,9H), 8.15 (s,2H) and 12.55 (s,1H).

10

Example 6**(±)-2-[[[2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol****(a) 7-Chloro-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-2-amine**

15 Prepared by the method of Example 1(a) from 2-amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one (product of Example 10).

m.p. 176.5-177.5°C

MS: APCI(+ve) 289 (M+1)

20 ¹H NMR: δ (DMSO) 0.88 (t,3H), 1.22-1.42 (m,4H), 1.60-1.74 (m,2H), 3.08 (t,2H) and 8.90 (s,2H).

(b) (±)-2-[[[2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol

Prepared by the method of Example 1(b) from the chloro compound of Example 6(a) and the appropriate amine.


m.p. 151-154°C

5 MS: APCI(+ve) 342 (M+1)

¹H NMR: δ (DMSO) 0.82-0.95 (m,6H), 1.22-1.72 (m,8H), 3.04 (m,2H), 3.39-3.56 (m,2H), 4.07 (m,1H), 4.64 (t,1H), 6.88 (d,1H), 7.44 (br s,1H) and 7.96 (s,2H).

Example 7

10 2-[[2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethanol



Prepared by the method of Example 6(b).


m.p. 192-195°C

15 MS: APCI(+ve) 314 (M+1)

¹H NMR: δ (DMSO) 0.87 (t,3H), 1.21-1.42 (m,4H), 1.57-1.70 (m,2H), 2.99 (t,2H), 3.37-3.46 (m,2H), 3.46-3.58 (m,2H), 4.71 (t,1H), 7.22 (t,1H) and 7.97 (s,2H).

Example 8

20 5-(Pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one



Prepared by the method of Example 4.


m.p. 208-209°C

25 MS: APCI(+ve) 256 (M+1)

¹H NMR: δ (DMSO) 0.88 (t,3H), 1.22-1.44 (m,4H), 1.63-1.75 (m,2H), 3.20 (t,2H), 9.57 (s,1H) and 13.06 (s,1H).

Example 9

5 **2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**



(a) 6-Amino-2-[(phenylmethyl)thio]-5-thiocyanato-4(1*H*)-pyrimidinone

6-Amino-2-[(phenylmethyl)thio]-4(1*H*)-pyrimidinone (10.5g) (prepared as described in WO 96/35678) and potassium thiocyanate (25g) in dimethylformamide (200mL) were
10 heated together at 65°C. Pyridine (6.3mL) was added and the solution cooled to 5°C. Bromine (2.2mL) was added slowly and the reaction mixture stirred for 2 hours at 5-10°C. The reaction mixture was poured onto ice and water, stirred for 1 hour and the solid was filtered off. After washing with water and ether a pure sample was obtained after titration with hot methanol.

15

m.p. 260-262°C

MS: APCI(+ve) 291 (M+1)

¹H NMR: δ (DMSO) 4.38 (s,2H), 7.21-7.51 (m,5H), 7.70 (br s,2H) and 12.35 (s,1H).

20 **(b) 2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**

The product of step (a) (7.35g) was heated at 120°C in dimethylformamide (40mL) and water (10mL) for 10 hours. After cooling, the resulting solid was filtered off, washed with water, ether and ethyl acetate to give the title compound containing 0.4 moles of dimethylformamide.

25


m.p. ~325°

MS: APCI(+ve) 291 (M+1)

^1H NMR: δ (DMSO) 4.41 (s,2H), 7.21-7.50 (m,5H), 8.17 (s,2H) and 12.53 (br s,1H).

Example 10

2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one



(a) 6-Amino-2-(pentylthio)-5-thiocyanato-4(1*H*)-pyrimidinone

Prepared by the method of Example 9(a).

m.p. 260-262°C

MS: APCI(+ve) 214 (M+1)

^1H NMR: δ (DMSO) 0.86 (t,3H), 1.22-1.40 (m,4H), 1.56-1.68 (m,2H), 3.10 (t,2H), 7.58 (br s,2H) and 12.30 (s,1H).

(b) 2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one


Prepared by the method of Example 9(b).

MS: APCI(+ve) 271 (M+1)

^1H NMR: δ (DMSO) 0.86 (t,3H), 1.24-1.40 (m,4H), 1.58-1.70 (m,2H), 3.12 (t,2H), 8.12 (br s,2H) and 12.49 (s,1H).

Example 11

2-Bromo-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one



Trimethylsilyl bromide (0.44mL) was added slowly to a solution at 0°C under nitrogen of t-butyl nitrite (0.42mL) in acetonitrile (2mL). After 30 minute at 0°C, 2-amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one (0.5g) (product of Example 10) was added.

The reaction mixture was stirred at room temperature for 16 hours and the solvent was evaporated. Chromatography on silica eluting with dichloromethane/methanol mixtures gave the title bromide.

5 m.p. 189-191°C

MS: APCI(+ve) 336/7 (M+1)


¹H NMR: δ (DMSO) 0.88 (t,3H), 1.26-1.41 (m,4H), 1.64-1.75 (m,2H), 3.18 (t,2H) and 13.22 (s,1H).

10 Examples 12-26

The compounds of Examples 12 to 26 were prepared by heating 2-bromo-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one (product of Example 11) with 5 equivalents of the appropriate amine in tetrahydrofuran at 45°C for 5 hours.

15 Example 12

2-[[3-(Dimethylamino)propyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one




MS: APCI (+ve) 356 (M+1)

20


Example 13

2-[[2-(Diethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one




MS: APCI (+ve) 370 (M+1)

25

Example 14**2-[[2-(Dimethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**


MS: APCI (+ve) 342 (M+1)

5

Example 15**2-[(3-Hydroxypropyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**


MS: APCI (+ve) 329 (M+1)

10

Example 16**2-[[2-(Acetylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**


MS: APCI (+ve) 356 (M+1)

15

Example 17**(±)-2-[(2,3-Dihydroxypropyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**


MS: APCI (+ve) 345 (M+1)

20

Example 18**2-[[2-(4-Morpholinyl)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**


MS: APCI (+ve) 384 (M+1)

5

Example 19**2-[(2-Methoxyethyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**


MS: APCI (+ve) 329 (M+1)

10

Example 20**2-[(1-Methylethyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**

MS: APCI (+ve) 313 (M+1)

15


Example 21**2-(Cyclopropylamino)-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**

MS: APCI (+ve) 311 (M+1)

20

Example 22

(±)-2-[(2-Hydroxypropyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one




MS: APCI (+ve) 329 (M+1)

5

Example 23


2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one



10 MS: APCI (+ve) 359 (M+1)

Example 24

2-[(2-Hydroxy-2-methylpropyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one




15

MS: APCI (+ve) 343 (M+1)

Example 25

2-[(2-Hydroxyethyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one




20

MS: APCI (+ve) 315 (M+1)

Example 26

(2*S*,3*R*)-3-Hydroxy-2-[(7-oxo-5-(pentylthio)-4*H*-thiazolo[4,5-*d*]pyrimidin-2-yl)-amino]butanamide



5 MS: APCI (+ve) 372 (M+1)

Examples 27-43

The compounds of Examples 27 to 43 were prepared by heating 7-chloro-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-2-amine (product of Example 6, step a) with 5
10 equivalents of the appropriate amine in tetrahydrofuran at 45°C for 5 hours.

Example 27


*N*⁷-[3-(Dimethylamino)propyl]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine




15 MS: APCI (+ve) 355 (M+1)

Example 28

*N*⁷-[2-(Diethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine




20 MS: APCI (+ve) 369 (M+1)

Example 29***N*⁷-[2-(Dimethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine**


MS: APCI (+ve) 341 (M+1)

5

Example 30**3-[(2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl)amino]-1-propanol**


MS: APCI (+ve) 328 (M+1)

10

Example 31***N*⁷-Cyclohexyl-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine**

MS: APCI (+ve) 352 (M+1)

15


Example 32**(±)-3-[(2-Amino-5-((phenylmethyl)thio)thiazolo[4,5-*d*]pyrimidin-7-yl)amino]-1,2-propanediol**

20

MS: APCI (+ve) 344 (M+1)

Example 33


***N*⁷-(2-Methoxyethyl)-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine**



5 MS: APCI (+ve) 328 (M+1)

Example 34


5-(Pentylthio)-*N*⁷-propylthiazolo[4,5-*d*]pyrimidine-2,7-diamine



10 MS: APCI (+ve) 312 (M+1)

Example 35


***N*⁷-Cyclopentyl-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine**



15 MS: APCI (+ve) 338 (M+1)

Example 36


***N*⁷-Cyclopropyl-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine**



20 MS: APCI (+ve) 310 (M+1)

Example 37


*N*⁷-(2-Methylpropyl)-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine



5 MS: APCI (+ve) 326 (M+1)

Example 38


(±)-1-[(2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl)amino]-2-propanol



10 MS: APCI (+ve) 328 (M+1)

Example 39


(exo)-*N*⁷-Bicyclo[2.2.1]hept-2-yl-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine




15 MS: APCI (+ve) 364 (M+1)

Example 40

2-[2-[[2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethoxy]ethanol




20 MS: APCI (+ve) 358 (M+1)

Example 41**(±)-*N*⁷-(2-Methylbutyl)-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine**


MS: APCI (+ve) 340 (M+1)

5

Example 42**1-[[2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-2-propanol**

MS: APCI (+ve) 342 (M+1)

10

Example 43***N*⁷-[(2-Aminophenyl)methyl]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine**


MS: APCI (+ve) 375 (M+1)

15

Examples 44-47


The compounds of Examples 44 to 47 were prepared from 2-amino-5,6-dihydro-5-thioxothiazolo[4,5-*d*]pyrimidin-7(4*H*)-one, diisopropylethylamine and the appropriate alkyl halide in dimethyl sulphoxide/dimethylformamide at 60°C. A total of 5 equivalents of base and alkyl halide were added over 3 days.

20

Example 44**2-Amino-5-[(2-phenoxyethyl)thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**


MS: APCI (+ve) 321 (M+1)

5

Example 45**(*E*)-2-Amino-5-[(3-phenyl-2-propenyl)thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**

MS: APCI (+ve) 317 (M+1)


10

Example 46**2-Amino-5-[[3-[2,4-bis(1,1-dimethylethyl)phenoxy]propyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**

15 MS: APCI (+ve) 447 (M+1)

Example 47

2-Amino-5-[[[(4-trifluoromethyl)phenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one




5 MS: APCI (+ve) 359 (M+1)

Examples 48-65

The compounds of Examples 48 to 65 were prepared from 2-amino-5,6-dihydro-5-thioxothiazolo[4,5-*d*]pyrimidin-7(4*H*)-one (product of Example 3, step a), potassium
10 t-butoxide and the appropriate benzyl halide in dimethyl sulphoxide at room temperature. A total of 1.2 equivalents of base and alkyl halide were used and a reaction time of 24 hours.

Example 48


15 **2-Amino-5-[[[(3,5-dichlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**



MS: APCI (+ve) 359 (M+1)

Example 49


20 **2-Amino-5-[[[(2,4-dichlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**



MS: APCI (+ve) 359 (M+1)

Example 50

2-Amino-5-[[[(3,4-dichlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one




5

MS: APCI (+ve) 359 (M+1)

Example 51

2-Amino-5-[[[(3,5-dibromophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one




10

MS: APCI (+ve) 449 (M+1)


Example 52

2-Amino-5-[[[(2-nitrophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one




15

MS: APCI (+ve) 336 (M+1)

Example 53**2-Amino-5-[[(2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**


MS: APCI (+ve) 309 (M+1)

5

Example 54**2-Amino-5-[[(2-iodophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**


MS: APCI (+ve) 417 (M+1)

10

Example 55**2-Amino-5-[[(3-chlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**


MS: APCI (+ve) 325 (M+1)

15

Example 56**2-Amino-5-[[(2-chlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**


MS: APCI (+ve) 325 (M+1)

20


Example 57**2-Amino-5-[[[(4-chloro-2-nitrophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**

MS: APCI (+ve) 370 (M+1)


5

Example 58**2-Amino-5-[[[(3-chloro-4-methoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**

10 MS: APCI (+ve) 355 (M+1)

Example 59**2-Amino-5-[[[(2,3-dichlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**


15 MS: APCI (+ve) 359 (M+1)

Example 60**2-Amino-5-[[[(3,5-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**

MS: APCI (+ve) 327 (M+1)

Example 61


2-Amino-5-[[[(2,4-bis(trifluoromethyl)phenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one



MS: APCI (+ve) 427 (M+1)

Example 62


2-Amino-5-[[[(2-bromophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one




MS: APCI (+ve) 371 (M+1)

Example 63

2-Amino-5-[[[(2,3,4-trifluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one




MS: APCI (+ve) 345 (M+1)

Example 64**2-Amino-5-[[[(3-bromophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**

MS: APCI (+ve) 369 (M+1)

5

Example 65**2-Amino-5-[[[(2-fluoro-3-methylphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**

10 MS: APCI (+ve) 323 (M+1)


Examples 66-77

The compounds of Examples 66 to 77 were prepared from 7-chloro-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-amine and the appropriate hydroxyamine in dimethyl sulphoxide at 45°C. A total of 6 equivalents of amine were added and the reaction time was 2 days.

15

Example 66**3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2,2-dimethyl-1-propanol**


20



MS: APCI (+ve) 376 (M+1)

Example 67

(±)-α-[[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]methyl]benzenemethanol




5

MS: APCI (+ve) 410 (M+1)

Example 68

(*R*)-β-[[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]benzenepropanol

10




MS: APCI (+ve) 424 (M+1)

Example 69

2-[[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethanol


15



MS: APCI (+ve) 334 (M+1)

Example 70

(2*R*)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]4-methylpentanol




5

MS: APCI (+ve) 390 (M+1)

Example 71

(±)-1-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol

10




MS: APCI (+ve) 348 (M+1)

Example 72

(±)-β-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-chlorobenzenepropanol


15



MS: APCI (+ve) 458 (M+1)

Example 73


(±)-3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,2-propanediol



MS: APCI (+ve) 364 (M+1)

Example 74


2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-propylamino]ethanol




MS: APCI (+ve) 376 (M+1)

Example 75

(±)-1-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-pyrrolidinol




MS: APCI (+ve) 360 (M+1)

Example 76**(±)-1-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinol**

MS: APCI (+ve) 374 (M+1)

5

Example 77**1-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-piperidinol**

MS: APCI (+ve) 374 (M+1)

10


Examples 78-110

The compounds of Examples 78 to 110 were prepared from 7-chloro-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-2-amine (prepared by the method of Example 1, step a) using the product of Example 5) and the appropriate hydroxyamine in tetrahydrofuran at 45°C. A total of 6 equivalents of amine were added and the reaction time was 2 days.

15

Example 78


3-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2,2-dimethyl-1-propanol



5 MS: APCI (+ve) 468 (M+1)

Example 79

(±)-2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol




10

MS: APCI (+ve) 454 (M+1)

Example 80

(±)-α-[[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]methyl]benzenemethanol


15



MS: APCI (+ve) 502 (M+1)

Example 81


4-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol



5 MS: APCI (+ve) 454 (M+1)

Example 82

6-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-hexanol




10

MS: APCI (+ve) 482 (M+1)

Example 83

4-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-amino]cyclohexanol


15



MS: APCI (+ve) 480 (M+1)

Example 84


(R)- β -[[2-Amino-5-[[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-amino]benzenepropanol



5 MS: APCI (+ve) 516 (M+1)

Example 85

(\pm)-2-[[2-Amino-5-[[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-amino]-1-propanol




10

MS: APCI (+ve) 440 (M+1)

Example 86

2-[[2-Amino-5-[[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-amino]ethanol


15



MS: APCI (+ve) 426 (M+1)

Example 87


(2R)-2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-amino]-4-methylpentanol



5 MS: APCI (+ve) 482 (M+1)

Example 88

(±)-1-Amino-3-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol




10

MS: APCI (+ve) 455 (M+1)

Example 89

(±)-1-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol


15



MS: APCI (+ve) 440 (M+1)

Example 90


2-[[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]methyl]-2-ethyl-1,3-propanediol



5 MS: APCI (+ve) 498 (M+1)

Example 91

(±)-β-[[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-chlorobenzenepropanol




10

MS: APCI (+ve) 550 (M+1)

Example 92

(±)-3-[[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,2-propanediol


15



MS: APCI (+ve) 456 (M+1)

Example 93


2-[[2-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethyl]amino]ethanol



5 MS: APCI (+ve) 469 (M+1)

Example 94

3-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol




10

MS: APCI (+ve) 440 (M+1)

Example 95

(±)-α-[[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]methyl]-3,4-dichlorobenzenepropanol


15



MS: APCI (+ve) 598 (M+1)

Example 96


1-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-2-propanol



5 MS: APCI (+ve) 454 (M+1)

Example 97

2-[2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethoxy]ethanol




10

MS: APCI (+ve) 470 (M+1)

Example 98

5-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol


15



MS: APCI (+ve) 468 (M+1)

Example 99


(2*S*)-2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-(methylthio)-1-butanol



5 MS: APCI (+ve) 500 (M+1)

Example 100

2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]butylamino]ethanol




10

MS: APCI (+ve) 482 (M+1)

Example 101

2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]propylamino]ethanol


15



MS: APCI (+ve) 468 (M+1)

Example 102


2,2'-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]imino]bisethanol



5 MS: APCI (+ve) 470 (M+1)

Example 103

2-[[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-(2-hydroxyethyl)amino]methyl]phenol




10

MS: APCI (+ve) 532 (M+1)

Example 104

3-[[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-(2-hydroxyethyl)amino]-1-propanol


15



MS: APCI (+ve) 484 (M+1)

Example 105


(±)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-pyrrolidinol



5 MS: APCI (+ve) 452 (M+1)

Example 106

(*trans*)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-hydroxy-*L*-proline phenylmethyl ester




10

MS: APCI (+ve) 586 (M+1)

Example 107

(±)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinemethanol


15



MS: APCI (+ve) 480 (M+1)

Example 108


(±)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinol



5 MS: APCI (+ve) 466 (M+1)

Example 109

(2*S*)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-2-pyrrolidinemethanol




10

MS: APCI (+ve) 466 (M+1)

Example 110

1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-piperidinol


15



MS: APCI (+ve) 466 (M+1)

Example 111

(2R)-2-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol



- 5 **(a) 7-chloro-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-2-amine**
Prepared by the method of Example 1(a).

m.p. 178-180°C

MS: APCI (+ve) 401 (M+1)

10 ¹H NMR: δ (DMSO) 4.37 (s,2H), 6.83-7.39 (m,9H) and 8.95 (s,2H).

(b) (2R)-2-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol

Prepared by the method of Example 1(b).

15

m.p. 108-111°C


MS: APCI (+ve) 454 (M+1)

¹H NMR: δ (DMSO) 0.81 (t,3H), 1.41 (m,2H), 1.62 (m,2H), 3.36 (m,2H), 4.03 (m,1H),
4.31 (q,2H), 4.62 (s,1H), 6.78-7.38 (m,9H) and 8.00 (s,2H).

20

Example 112

(2*S*)-2-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol



5 Prepared by the method of Example 1(b).


m.p. 111-114°C

MS: APCI (+ve) 454 (M+1)

¹H NMR: δ (DMSO) 0.81 (t, 3H), 1.41 (m, 2H), 1.62 (m, 2H), 3.36 (m, 2H), 4.02 (br d, 1H),
 10 4.32 (q, 2H), 4.60 (s, 1H), 6.79-7.40 (m, 9H) and 8.04 (s, 2H).

Example 113

(2*R*)-2-[[2-Amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol



15

(a) 7-Chloro-5-[[3,4-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-2-amine

Prepared by the method of Example 1(a) using the product of Example 3.

m.p. 209-210°C

20 MS: APCI(+ve) 345/6 (M+1)

¹H NMR: δ (DMSO) 4.45 (s, 2H), 7.10-7.42 (m, 3H) and 8.90 (br s, 2H).

(b) **(2*R*)-2-[[2-Amino-5-[[[(3,4-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol**


Prepared by the method of Example 1(b) using the product of step a) above.

5 MS: APCI(+ve) 398 (M+1)

¹H NMR: δ (DMSO) 0.82 (t,3H), 1.34-1.71 (m,4H), 3.37 (m,2H), 4.03 (br d,1H), 4.38 (q,2H), 4.62 (t,1H), 6.96 (d,1H), 7.06-7.40 (m,3H) and 8.02 (s,2H).

Example 114

10 **2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,3-propanediol**



Prepared by the method of Example 1(b).


15 m.p. 220-222°C

MS: APCI (+ve) 456 (M+1)

¹H NMR: δ (DMSO) 3.50 (t,4H), 4.13 (m,1H), 4.32 (s,2H), 4.60 (t,2H), 6.78-7.40 (m,10H) and 8.01 (s,2H).

20 **Example 115**

2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol



Prepared by the method of Example 1(b) with 10 equivalents of amine, 45-65°C and reaction time of 3 weeks. Purification by chromatography on silica eluting with methanol/dichloromethane mixtures gave the title compound.


5 m.p. 126-130°C

MS: APCI (+ve) 454 (M+1)

¹H NMR: δ (DMSO) 1.30 (s,6H), 3.53 (d,2H), 4.33 (s,2H), 4.86 (t,1H), 6.28 (s,1H), 6.80-7.40 (m,9H) and 8.00 (s,2H).

10 **Example 116**

2-[[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol



Prepared by the method of Example 1(b) using the product of Example 113, step a), 10 equivalents of amine, 45-65°C and reaction time of 3 weeks. Purification by chromatography on silica eluting with methanol/dichloromethane mixtures gave the title compound.

m.p. 231-234°C

20 MS: APCI (+ve) 398 (M+1)

¹H NMR: δ (DMSO) 1.30 (s,6H), 3.53 (d,2H), 4.40 (s,2H), 4.84 (t,1H), 6.32 (s,1H), 7.10-7.40 (m,3H) and 8.03 (s,2H).

Example 117**1-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-2-propanol**

5 The product from Example 113, step a) (0.1g) and 1-amino-2-methyl-propan-2-ol (0.5g) in tetrahydrofuran (10ml) was heated in a sealed vessel at 100 °C for 18 hours. The mixture was evaporated to dryness and purified (HPLC, Novapak[®] C18 column, 0.1% aqueous ammonium acetate:acetonitrile, gradient elution 70:30 to 0:100 over 15 minutes) to afford the title compound (0.051g).

10

MS (APCI) 398 (M+H⁺, 100%).

NMR δH (d₆-DMSO) 8.05 (2H, s), 7.39-7.17 (2H, m), 7.16-7.05 (2H, m), 4.51 (1H, s), 5.23 (1H, d), 4.39 (2H, s), 3.37 (2H, d), 1.06 (6H, s).

15 **Example 118****5-[[[(2,3-Difluorophenyl)methyl]thio]-*N*⁷-(2-fluoroethyl)thiazolo[4,5-*d*]pyrimidine-2,7-diamine**

The product from Example 113, step a) (0.1g), 2-fluoroethylamine hydrochloride (0.5g)
20 and *N,N*-ethyldiisopropylamine (0.4ml) in tetrahydrofuran:water (7ml, 5:2) was heated in a sealed vessel at 100 °C for 18 hours. The mixture was evaporated to dryness and purified (HPLC, Novapak[®] C18 column, 0.1% aqueous ammonium acetate:acetonitrile, gradient elution 70:30 to 0:100 over 15 minutes) to afford the title compound (0.027g).

25

MS (APCI) 372 (M+H⁺, 100%).

NMR δH (d₆-DMSO) 8.09 (2H, s), 7.36 (1H, t), 7.38-7.10 (3H, m), 4.57 (1H, t), 4.21 (3H,m), 3.71 (1H, q), 4.39 (2H, s), 3.63 (1H, q).

Example 119

(1*R*-trans) 2-[[2-Amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-cyclopentanol

- 5 The product from example 113 step a) (0.2g), (*1R,2R*) 2-aminocyclopentanol hydrochloride (1.0g) and *N*-ethyl-diisopropylamine (1.2ml) in methanol (15ml) was heated in a sealed vessel at 120 °C for 90 mins. The mixture was evaporated to dryness and purified (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate:acetonitrile, gradient elution 70:30 to 0:100 over 15 minutes) to afford the title compound (0.098g).

10

MS (APCI) 410 ($M+H^+$, 100%).

NMR δ H (d_6 -DMSO) 8.04 (2H, s), 7.41-7.27 (2H, m), 7.20 (1H, d), 7.16-7.11 (1H, m), 4.76 (1H, d), 4.41 (2H, dd), 4.09 (1H, m), 3.95 (1H, m), 1.99 (1H, m), 1.89 (1H, m), 1.62 (2H, m), 1.49-1.36 (2H, m).

15

Example 120

(1*S*-trans) 2-[[2-Amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-cyclopentanol

- 20 Prepared by the method of Example 119 using the product from Example 113, step a) and (*1S,2S*)-2-aminocyclopentanol hydrochloride.

MS (APCI) 410 ($M+H^+$, 100%).

- 25 NMR δ H (d_6 -DMSO) 8.03 (2H, s), 7.41-7.27 (2H, m), 7.20 (1H, d), 7.16-7.11 (1H, m), 4.76 (1H, d), 4.41 (2H, dd), 4.09 (1H, m), 3.96 (1H, m), 1.99 (1H, m), 1.89 (1H, m), 1.62 (2H, m), 1.49-1.36 (2H, m).

Example 121**2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol**

5 Prepared by the method of Example 117 using the product of Example 1, step a) (0.6g) and 2-amino-2-methyl-propanol. Purification (SiO₂, ethyl acetate as eluant) gave the title compound (0.46g).

MS (APCI) 362 (M+H⁺, 100%).

10 NMR δ H (d₆-DMSO) 8.00 (2H, s), 7.42-7.20 (5H, m), 6.29 (1H, s), 4.86 (1H, s), 4.35 (2H, s), 3.56 (2H, d), 1.32 (6H, s).

Example 122**2-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol****a) 2-[[2-Bromo-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol**

20 To a solution of the product from Example 121 (0.1g) in bromoform (5 ml) was added isoamyl nitrite (0.13 ml) and the mixture heated at 60°C for 10 mins. The mixture was evaporated to dryness then purified (SiO₂, ethyl acetate: dichloromethane 1:9 as eluant) to give the subtitle compound (0.043g).

25 MS (APCI) 426 (M+H⁺, 100%).

b) 2-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

To a solution of the product from step a) (0.043g) in methanol (5ml) was added a saturated solution of methanolic methylamine (20ml) and the mixture stirred for 30 mins. The mixture was evaporated to dryness and purified (HPLC, Novapak[®] C18 column, 0.1% aqueous ammonium acetate:acetonitrile, isocratic elution 70:30 over 15 minutes) to afford the title compound (0.026g).

MS (APCI) 376 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 8.49 (1H, d), 7.42-7.21 (5H, m), 6.34 (1H, s), 4.87 (1H, s), 4.35 (2H, s), 3.56 (2H, d), 2.94 (3H, d), 1.33 (6H, s).

Example 123

2-[[2-[[5-[(2,3-Difluorophenyl)methyl]thio]-2-[(phenylmethyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

a) 2-[[2-Bromo-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

The sub-title compound was prepared by the method of Example 122, step a) using the product from Example 116. Purification (SiO₂, ethyl acetate: dichloromethane 1:9 as eluant) gave the subtitle compound (0.16g).

MS (APCI) 461 (M+H⁺, 100%).

b) 2-[[2-[[5-[(2,3-Difluorophenyl)methyl]thio]-2-[(phenylmethyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

Prepared by the method of Example 122, step b) using the product from step a).

Purification (SiO₂, ethyl acetate: dichloromethane 1:9 as eluant) gave the title compound (0.051g).

MS (APCI) 488 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 9.08(1H, d), 7.38-7.12 (8H, m), 6.42 (1H, s), 4.82 (1H, t), 4.59 (2H, s), 4.42 (2H, s), 3.54 (2H, d), 1.29 (6H, s).

5 **Example 124**

5-[[[(2,3-Difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one

To a solution of the product from Example 3 (1.0g) in tetrahydrofuran (50ml) was added isoamyl nitrite (3ml) and the mixture heated at 70°C for 2 hours. The mixture was
10 evaporated to dryness and purified (SiO₂, ethyl acetate: chloroform 1:9 as eluant) to give the title compound (0.61g).

MS (APCI) 512 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 13.19(1H, s), 9.61(1H, d), 7.44-7.33 (2H, m), 7.22-15 (1H, m), 4.59
15 (2H, s).

Example 125-148

Example 125 to 148 were prepared by heating, the product of Example 113, step a) (5x10⁻⁶
20 moles) with the appropriate amine (10 equivalents) and *N*-ethyldiisopropylamine (20 equivalents) in *N*-methylpyrrolidinone (0.3 ml) in a sealed vessel at 120°C for 16 hours.

Example 125

(±)-2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-
25 yl]amino]-1-butanol

MS (APCI) 398 (M+H⁺, 100%).

Example 126

(1*S*,2*S*)-2-[[2-Amino-5-[[*(*2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-cyclohexanol

5 MS (APCI) 424 ($M+H^+$, 100%).

Example 127

(±)-2-[[2-Amino-5-[[*(*2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

10

MS (APCI) 384 ($M+H^+$, 100%)

Example 128

2-[[2-Amino-5-[[*(*2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-ethanol

15

MS (APCI) 370 ($M+H^+$, 100%).

Example 129

(2*R*)-2-[[2-Amino-5-[[*(*2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol

20

MS (APCI) 426 ($M+H^+$, 100%).

Example 130

(±)-1-[[2-Amino-5-[[*(*2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol

25

MS (APCI) 384 ($M+H^+$, 100%).

30

Example 131

2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1,3-propanediol

5 MS (APCI) 414 ($M+H^+$, 100%).

Example 132

1-[[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]methyl]-cyclohexanol

10

MS (APCI) 438 ($M+H^+$, 100%).

Example 133

(2*R*)-2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol

15

MS (APCI) 398 ($M+H^+$, 100%).

Example 134

2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-(2-aminoethyl)amino]-1-ethanol

20

MS (APCI) 413 ($M+H^+$, 100%).

Example 135

2-[2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethoxy]-1-ethanol

25

MS (APCI) 414 ($M+H^+$, 100%).

30

Example 136

**(α S)- α -[(1R)-1-[[2-Amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-
d]pyrimidin-7-yl)methylamino]ethyl]-benzenemethanol**

5 MS (APCI) 474 (M+H⁺, 100%).

Example 137

**1-[2-Amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-
piperidinol**

10

MS (APCI) 410 (M+H⁺, 100%).

Example 138

5-[[2,3-Difluorophenyl)methyl]thio]-N⁷-ethyl-thiazolo[4,5-d]pyrimidine-2,7-diamine

15

MS (APCI) 354 (M+H⁺, 100%).

Example 139

**5-[[2,3-Difluorophenyl)methyl]thio]-N⁷-(2-propenyl)-thiazolo[4,5-d]pyrimidine-2,7-
diamine**

20

MS (APCI) 366 (M+H⁺, 100%).

Example 140

25 **2-Bromo-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one**

To a solution of the product from Example 9 (2g) in bromoform (100ml) was added
isoamyl nitrite (2ml) and the mixture heated at 80°C for 2 hour. The mixture was
evaporated to dryness and purified (SiO₂, dichloromethane as eluant) to give the title
30 compound (0.76g).

MS (APCI) 355, 354 ($M+H^+$), 354 (100%).

Example 141

5 (1*S*,2*S*)-2-[[2-Amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-phenyl-1,3-propanediol

MS (APCI) 476 ($M+H^+$, 100%).

10 **Example 142**

2-[[2-Amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,3-propanediol

MS (APCI) 400 ($M+H^+$, 100%).

15

Example 143

2-[[2-Amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-ethanol

20 MS (APCI) 370 ($M+H^+$, 100%).

Example 144

(±)-5-[[2,3-Difluorophenyl)methyl]thio]-*N*⁷-(2-methoxy-1-methylethyl)-thiazolo[4,5-*d*]pyrimidine-2,7-diamine

25

MS (APCI) 398 ($M+H^+$, 100%).

Example 145

*N*⁷-Cyclopropyl-5-[[2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-*d*]pyrimidine-2,7-diamine

30

MS (APCI) 366 ($M+H^+$, 100%).

Example 146

5 **(±)-2-[[2-Amino-5-[[2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol**

MS (APCI) 384 ($M+H^+$, 100%).

10 **Example 147**

4-[[2-Amino-5-[[2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol

MS (APCI) 398 ($M+H^+$, 100%).

15

Example 148

5-[[2,3-Difluorophenyl)methyl]thio]-*N*⁷-[2-(1*H*-imidazol-4-yl)ethyl]-thiazolo[4,5-*d*]pyrimidine-2,7-diamine

20 MS (APCI) 420 ($M+H^+$, 100%).

Example 149-165

The compounds of Example 149 to 165 were prepared by heating 2-[[2-bromo-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol
25 (prepared according to the method of Example 122, step a) using the product of Example 116) (5×10^{-6} moles) with the appropriate amine (2 equivalents) and *N*-ethyl-diisopropylamine (2 equivalents) in tetrahydrofuran (0.5 ml) at 50-60°C for 16 hours.

Example 149

***N*-[5-[[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-*d*]pyrimidin-2-yl]-serine, methyl ester**

5 MS (APCI) 500 ($M+H^+$, 100%).

Example 150

2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(1-methylethyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

10

MS (APCI) 440 ($M+H^+$, 100%).

Example 151

2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-(ethylamino)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

15

MS (APCI) 426 ($M+H^+$, 100%).

Example 152

2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(1*H*-indol-3-yl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

20

MS (APCI) 541 ($M+H^+$, 100%).

Example 153

2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

25

30 MS (APCI) 538 ($M+H^+$, 100%).

Example 154

2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(1,2-diphenylethyl)amino]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

5

MS (APCI) 578 (M+H⁺, 100%).

Example 155

2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(2,2,2-trifluoroethyl)amino]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

10

MS (APCI) 480 (M+H⁺, 100%).

Example 156

2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[[[(3,4,5-
trimethoxyphenyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-
propanol

15

MS (APCI) 578 (M+H⁺, 100%).

20

Example 157

2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(1,1-dimethylethyl)amino]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

25

MS (APCI) 454 (M+H⁺, 100%).

Example 158

2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

30

MS (APCI) 508 (M+H⁺, 100%).

Example 159

2-[[5-[[2,3-Difluorophenyl)methyl]thio]-2-[(4-methylcyclohexyl)amino]thiazolo[4,5-
5 *d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 494 (M+H⁺, 100%).

Example 160

10 2-[[5-[[2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-
dimethylethyl)amino]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-acetamide

MS (APCI) 455 (M+H⁺, 100%).

15 **Example 161**

2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[2,3-
difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-
propanol

20 MS (APCI) 517 (M+H⁺, 100%).

Example 162

2-[[5-[[2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

25

MS (APCI) 444 (M+H⁺, 100%).

Example 163

2-[[2-(Cyclopropylamino)-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-
30 *d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 438 ($M+H^+$, 100%).

Example 164

5 **(±)-2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-pentanol**

MS (APCI) 484 ($M+H^+$, 100%).

10 **Example 165**

2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-hydroxyethoxy)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

15 MS (APCI) 486 ($M+H^+$, 100%).

Example 166

2-Bromo-5-[[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one

20 To a solution of the product from Example 3 (0.2g) in bromoform (5ml) was added isoamyl nitrite (0.25ml) and the mixture heated at 70°C for 1 hour. The mixture was evaporated to dryness and purified (SiO₂, dichloromethane as eluant) to give the title compound (0.08g).

25 NMR δ H (d₆-DMSO) 7.42-7.14 (3H, m), 4.55 (2H, s).

Example 167-173

The compounds of Example 167 to 173 were prepared by heating, the product of Example 166 with the appropriate amine (1.2 equivalents) and *N*-ethyl-diisopropylamine (0.1 ml) in tetrahydrofuran (0.2 ml) at 40°C for 16 hours.

Example 167

N-[5-[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-*d*]pyrimidin-2-yl]-DL-serine, methyl ester

MS (APCI) 429 (M+H⁺, 100%).

Example 168

5-[(2,3-Difluorophenyl)methyl]thio]-2-[(1-methylethyl)amino]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one

MS (APCI) 369 (M+H⁺, 100%).

Example 169

5-[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(1*H*-indol-3-yl)ethyl]amino]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one.

MS (APCI) 470 (M+H⁺, 100%).

Example 170

2-[[5-[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-acetamide

MS (APCI) 384 (M+H⁺, 100%).

Example 171

2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one

5 MS (APCI) 446 (M+H⁺, 100%).

Example 172

5-[[2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one

10

MS (APCI) 373 (M+H⁺, 100%).

Example 173

**5-[[2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-hydroxyethoxy)ethyl]amino]-
15 thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**

MS (APCI) 415 (M+H⁺, 100%).

Example 174-218

20

Example 174 to 218 were prepared by heating the product of Example 122, step a) (5×10^{-6} moles) with the appropriate amine (2 equivalents) and *N*-ethyldiisopropylamine (2 equivalents) in *N*-methylpyrrolidinone (0.1 ml) in a sealed vessel at 60°C for 5 hours.

25

Example 174

**2-[[2-(Cyclohexylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-
2-methyl-1-propanol**

MS (APCI) 444 (M+H⁺, 100%).

30

Example 175

2-[[2-[(1,1-Dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

5 MS (APCI) 418 (M+H⁺, 100%).

Example 176

***N*-[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]-DL-alanine, methyl ester**

10

MS (APCI) 448 (M+H⁺, 100%).

Example 177

4-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-cyclohexanol

15

MS (APCI) 460 (M+H⁺, 100%).

Example 178

2-Methyl-2-[[2-[(4-phenylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

20

MS (APCI) 494 (M+H⁺, 100%).

Example 179

2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

25

MS (APCI) 446 (M+H⁺, 100%).

30

Example 180

2-Methyl-2-[[2-[(1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

5 MS (APCI) 404 ($M+H^+$, 100%).

Example 181

2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

10

MS (APCI) 481 ($M+H^+$, 100%).

Example 182

***N*-[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]-L-valine, ethyl ester**

15

MS (APCI) 490 ($M+H^+$, 100%).

Example 183

(2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-4-methyl-pentanamide.

20

MS (APCI) 475 ($M+H^+$, 100%).

Example 184

25

2-Methyl-2-[[2-[(2-phenylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

MS (APCI) 466 ($M+H^+$, 100%).

30

Example 185

2-[[2-[[4-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

5 MS (APCI) 467 (M+H⁺, 100%).

Example 186

2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-1-propanol

10

MS (APCI) 472 (M+H⁺, 100%).

Example 187

2-[[2-[(2-Fluoroethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-
15 yl]amino]-2-methyl-1-propanol

MS (APCI) 408 (M+H⁺, 100%).

Example 188

20 2-Methyl-2-[[2-[[3-nitrophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-1-propanol

MS (APCI) 497 (M+H⁺, 100%).

Example 189

(α R)- α -[(1S)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-
[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-benzenemethanol

MS (APCI) 496 (M+H⁺, 100%).

Example 190

2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[(3,4,5-trimethoxyphenyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

5 MS (APCI) 542 (M+H⁺, 100%).

Example 191

2-Methyl-2-[[2-[(1*R*-trans)-(2-phenylcyclopropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

10

MS (APCI) 478 (M+H⁺, 100%).

Example 192

2-[[2-[[2-(1*H*-Indol-3-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

15

MS (APCI) 505 (M+H⁺, 100%).

Example 193

2-[[2-[(1,1-Dimethylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

20

MS (APCI) 432 (M+H⁺, 100%).

Example 194

(±)-2-Methyl-2-[[2-[(1-methylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

25

MS (APCI) 432 (M+H⁺, 100%).

30

Example 195

(±)-2-Methyl-2-[[2-[(1-methylhexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

5 MS (APCI) 460 (M+H⁺, 100%).

Example 196

2-[[2-[[2-(2-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

10

MS (APCI) 467 (M+H⁺, 100%).

Example 197

2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1,3-propanediol

15

MS (APCI) 436 (M+H⁺, 100%).

Example 198

2-[[2-[[2-(Ethylthio)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

20

MS (APCI) 450 (M+H⁺, 100%).

Example 199

(2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-3,3-dimethyl-1-butanol

25

MS (APCI) 462 (M+H⁺, 100%).

30

Example 200

(α S)- α -[(1R)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-2-methoxyethyl]-benzenemethanol

5

MS (APCI) 526 (M+H⁺, 100%).

Example 201

2-[[2-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

10

MS (APCI) 390 (M+H⁺, 100%).

Example 202

2-[[2-[[[3-Fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

15

MS (APCI) 538 (M+H⁺, 100%).

Example 203

(\pm)-2-Methyl-2-[[2-[(1-methylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

20

MS (APCI) 418 (M+H⁺, 100%).

25

Example 204

2-[[2-[[[4-Methoxyphenyl]methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 482 (M+H⁺, 100%).

30

Example 205

2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

5

MS (APCI) 406 (M+H⁺, 100%).

Example 206

2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

10

MS (APCI) 456 (M+H⁺, 100%).

Example 207

2-[[2-[(Diphenylmethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

15

MS (APCI) 528 (M+H⁺, 100%).

Example 208

(2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-butanol

20

MS (APCI) 434 (M+H⁺, 100%).

25

Example 209

2-[[2-[(2,2-Diethoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 478 (M+H⁺, 100%).

30

Example 210

4-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-butanol

5

MS (APCI) 434 (M+H⁺, 100%).

Example 211

(1*S*,2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-

10 **[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-cyclohexanol.**

MS (APCI) 460 (M+H⁺, 100%).

Example 212

15 **(±)-2-[[2-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol**

MS (APCI) 420 (M+H⁺, 100%).

20 **Example 213**

2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

MS (APCI) 450 (M+H⁺, 100%).

25

Example 214

(±)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-pentanol

30 MS (APCI) 448 (M+H⁺, 100%).

Example 215

2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-acetamide

5

MS (APCI) 419 (M+H⁺, 100%).

Example 216

(±)-2-[[2-[[1-(4-Fluorophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-propanol

10

MS (APCI) 484 (M+H⁺, 100%).

Example 217

(1*R*,2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-cyclohexanol

15

MS (APCI) 460 (M+H⁺, 100%).

Example 218

(α*S*)-α-[(1*R*)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-benzenemethanol

20

MS (APCI) 496 (M+H⁺, 100%).

25

Example 219

2-Bromo-7-chloro-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidine

To a solution of the product from Example 1, step a) (10g) in bromoform (300ml) was added *t*-butylnitrite (10ml) and the mixture heated at 60°C for 30 mins. The mixture was

30

evaporated to dryness then purified (SiO₂, isohexane: dichloromethane 1:1 as eluant) to give the title compound (7.5g).

MS (APCI) 373 (M+H⁺, 100%).

5 NMR δH (d₆-DMSO) 7.47-7.24 (5H, m), 4.49 (2H, s).

Example 220

7-Chloro-*N*-methyl-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidin-2-amine

10 A solution of the product from Example 219 (0.3g) in tetrahydrofuran (2ml) containing methylamine (2.0 molar in THF:0.81ml) was stirred for 16 hours. The mixture was evaporated to dryness then purified (SiO₂, ethyl acetate:dichloromethane 1:9 as eluant) to give the title compound (295mg).

15 MS (APCI) 323 (M+H⁺, 100%).

NMR δH (d₆-DMSO) 9.30 (1H, s), 7.46-7.22 (5H, m), 4.40 (2H, s), 3.05 (3H, s).

Example 221-223

20 Examples 221 to 223 were prepared by heating the product of Example 220 (2.5x10⁻⁶ moles) with the appropriate amine (2 equivalents) and *N*-ethyldiisopropylamine (3 equivalents) in *N*-methylpyrrolidinone (0.1ml) in a sealed vessel at 100°C for 10 hours.

Example 221

25 (±)-2-[[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

MS (APCI) 362 (M+H⁺, 100%).

Example 222

(2*R*)-4-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol

5 MS (APCI) 404 (M+H⁺, 100%).

Example 223

***N*-[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-L-serine, ethyl ester**

10

MS (APCI) 420 (M+H⁺, 100%).

Example 224

7-Chloro-5-[(phenylmethyl)thio]-*N*-[(tetrahydro-2-furanyl)methyl]-thiazolo[4,5-*d*]pyrimidin-2-amine

15

Prepared according to the method of Example 220 using the product of Example 219 and tetrahydrofurfurylamine.

20 MS (APCI) 393 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 9.50 (1H, s), 7.47-7.19 (5H, m), 4.39 (2H, s), 4.06 (1H, m) 3.82 (1H, m), 3.66 (2H, m), 3.50 (1H, m), 2.00-1.53 (4H, m).

Examples 225-228

25

Examples 225-228 were prepared by the method of Example 221, using the product of Example 224.

Examples 225

(±)-2-[[5-[(Phenylmethyl)thio]-2-[[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol

5 MS (APCI) 446 (M+H⁺, 100%).

Examples 226

(±)-2-[[5-[(Phenylmethyl)thio]-2-[[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

10

MS (APCI) 432 (M+H⁺, 100%).

Examples 227

(2*R*)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[[(tetrahydro-2-
15 furanyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol

MS (APCI) 474 (M+H⁺, 100%).

Examples 228

20 *N*-[5-[(Phenylmethyl)thio]-2-[[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]-L-serine, ethyl ester

MS (APCI) 490 (M+H⁺, 100%).

Example 229

25 2-[2-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethoxy]-1-ethanol

Prepared according to the method of Example 220 using the product of Example 219 (0.3g)
30 and 2-(2-aminoethoxy)ethanol.

MS (APCI) 397 (M+H⁺, 100%).

Example 230

5 (±)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-1-propanol

Prepared by the method of Example 221, using the product of Example 229.

10 MS (APCI) 436 (M+H⁺, 100%).

Example 231

4-[2-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-
benzenesulfonamide

15

A solution of the product from Example 219 (0.3g) in tetrahydrofuran (2ml) containing 4-(2-aminoethyl)benzenesulfonamide (0.161 g) and *N*-ethyldiisopropylamine (0.5 ml) was stirred for 16 hours. The mixture was evaporated to dryness then purified (SiO₂, ethyl acetate:dichloromethane 4:6 as eluant) to give the title compound (310mg).

20

MS (APCI) 492 (M+H⁺, 100%).

NMR δH (d₆-DMSO) 9.45 (1H, s), 7.78-7.23 (9H, m), 4.41 (2H, s), 3.77 (2H, s) 3.02 (2H, t).

25 Examples 232-235

Examples 232-235 were prepared by the method of Example 221, using the product of Example 231.

Example 232

(±)-4-[2-[[7-[[1-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide

5 MS (APCI) 545 (M+H⁺, 100%).

Example 233

(±)-4-[2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide

10

MS (APCI) 531 (M+H⁺, 100%).

Example 234

4-[2-[[7-[(1*R*)-1-(Hydroxymethyl)-3-methylbutyl]amino]-5-
15 [(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide.

MS (APCI) 573 (M+H⁺, 100%).

Example 235

20 (±)-4-[2-[[7-[(2-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide

MS (APCI) 531 (M+H⁺, 100%).

25 **Example 236**

7-Chloro-*N*-[2-(1*H*-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidin-2-amine

Prepared according to the method of Example 231 using the product of Example 219 and
30 histamine.

MS (APCI) 403 (M+H⁺, 100%).

NMR δH (d₆-DMSO) 11.86 (1H, s), 9.42 (1H, s), 7.56 (1H, s), 7.56-7.23 (5H, m), 6.87 (1H, s), 4.41 (2H, s) 3.73 (2H, m), 2.85 (2H,t).

5

Examples 237-248

Examples 237-248 were prepared by the method of Example 221, using the product of Example 236.

10

Example 237

***N*⁷-Ethyl-*N*²-[2-(1*H*-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thiothiazolo[4,5-*d*]pyrimidine-2,7-diamine**

15 MS (APCI) 412 (M+H⁺, 100%).

Example 238

***N*²-[2-(1*H*-Imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]-*N*⁷-(3-pyridinylmethyl)-thiazolo[4,5-*d*]pyrimidine-2,7-diamine**

20

MS (APCI) 475 (M+H⁺, 100%).

Example 239

(±)-2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]- 1-butanol

25

MS (APCI) 456 (M+H⁺, 100%).

Example 240

(±)-2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

5 MS (APCI) 442 (M+H⁺, 100%).

Example 241

(2*R*)-2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol

10

MS (APCI) 484 (M+H⁺, 100%).

Example 242

(±)-1-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol

15

MS (APCI) 442 (M+H⁺, 100%).

Example 243

20 5-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol

MS (APCI) 470 (M+H⁺, 100%).

Example 244

25 1-[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-(phenylmethyl)-4-piperidinol

MS (APCI) 558 (M+H⁺, 100%).

30

Example 245

(±)-1-[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinecarboxamide

5 MS (APCI) 495 (M+H⁺, 100%).

Example 246

2-[Ethyl[2-[[2-(1*H*-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-ethanol

10

MS (APCI) 456 (M+H⁺, 100%).

Example 247

*N*²-[2-(1*H*-Imidazol-4-yl)ethyl]-*N*⁷,*N*⁷-dimethyl-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidine-2,7-diamine

15

MS (APCI) 412 (M+H⁺, 100%).

Example 248

*N*⁷-[2-(Diethylamino)ethyl]-*N*⁷-ethyl-*N*²-[2-(1*H*-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidine-2,7-diamine

20

MS (APCI) 511 (M+H⁺, 100%).

Example 249

7-Chloro-*N*-(2-phenoxyethyl)-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidin-2-amine

25

Prepared by the method of Example 231, using the product of Example 219 and 2-phenoxyethylamine.

30

MS (APCI) 429 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 9.65 (1H, s), 7.46-6.93 (10H, m), 4.41 (2H, s), 4.20 (2H, t), 3.87 (2H, m).

5

Examples 250-255

Examples 250-255 were prepared by the method of Example 221, using the product of Example 249.

10

Example 250

*N*²-(2-Phenoxyethyl)-5-[(phenylmethyl)thio]-*N*⁷-(3-pyridinylmethyl)-thiazolo[4,5-*d*]pyrimidine-2,7-diamine

15 MS (APCI) 501 (M+H⁺, 100%).

Example 251

*N*²-(2-Phenoxyethyl)-*N*⁷-[1-(phenylmethyl)-4-piperidinyl]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidine-2,7-diamine

20

MS (APCI) 583 (M+H⁺, 100%).

Example 252

2-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol.

25

MS (APCI) 482 (M+H⁺, 100%).

Example 253

(±)-2-[[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

5 MS (APCI) 468 (M+H⁺, 100%).

Example 254

(2*R*)-4-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol

10

MS (APCI) 510 (M+H⁺, 100%).

Example 255

1-[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-(phenylmethyl)-4-piperidinol.

15

MS (APCI) 584 (M+H⁺, 100%).

Example 256

20 7-Chloro-*N*-cyclopropyl-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidin-2-amine,

Prepared by the method of Example 220, using the product of Example 219 and cyclopropanamine.

25 MS (APCI) 351, 349 (M+H⁺, 100%).

NMR δH (d₆-DMSO) 7.46-7.22 (5H, m), 4.41 (2H, s), 2.85-2.80 (1H, m), 0.90-0.84 (2H, m), 0.71-0.66 (2H, m).

Examples 257-260

Example 257 to 260 were prepared by the method of Example 221 using the product of Example 256.

5

Example 257

2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo [4,5-*d*]pyrimidin-7-yl]amino]-1-butanol

10 MS (APCI) 402 ($M+H^+$, 100%).

Example 258

2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo [4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

15

MS (APCI) 388 ($M+H^+$, 100%).

Example 259

(2*R*)-2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo [4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol

20

MS (APCI) 430 ($M+H^+$, 100%).

Example 260

***N*-[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-L-serine, ethyl ester**

25

MS (APCI) 446 ($M+H^+$, 100%).

Example 261**2-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-pentanol**

Prepared by the method of Example 231, using the product of Example 219 and
5 2-amino-1-pentanol.

MS (APCI) 397, 395 ($M+H^+$, 100%).

1H NMR (d_6 -DMSO) δ 9.29 (1H, s), 7.46-7.22 (5H, m), 4.93 (1H, t), 4.39 (2H, s), 4.07-
4.00 (1H, m), 3.50 (2H, t), 1.63-1.43 (2H, m), 1.38-1.32 (2H, m), 0.89 (3H, t).

Examples 262-264

Example 262 to 264 were prepared by the method of Example 221 using the product of
Example 261.

Example 262**(2*R*)-2-[[2-[[1-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol**

MS (APCI) 476 ($M+H^+$, 100%).

Example 263***N*-[2-[[1-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-L-serine, ethyl ester**

MS (APCI) 492 ($M+H^+$, 100%).

Example 264**(\pm)-2-[[7-[Cyclohexyl(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-pentanol**

MS (APCI) 502 ($M+H^+$, 100%).

Examples 265-270

- 5 The following examples were prepared by the method of Example 221, using the product of Example 229.

Examples 265

- 10 **2-[2-[[7-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethoxy]-1-ethanol**

MS (APCI) 406 ($M+H^+$, 100%).

Examples 266

- 15 **2-[2-[[7-[(1-Methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethoxy]-1-ethanol**

MS (APCI) 420 ($M+H^+$, 100%).

Examples 267

- 20 **(±)-2-[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,**

MS (APCI) 450 ($M+H^+$, 100%).

Examples 268

- 2-[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol**

- 30 MS (APCI) 450 ($M+H^+$, 100%).

Examples 269

(2R)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,

5

MS (APCI) 478 (M+H⁺, 100%).

Examples 270

2-[Cyclohexyl-[2-[[2-(2-hydroxyethoxy)ethyl]amino]-5-

10 [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-ethanol

MS (APCI) 504 (M+H⁺, 100%).

Examples 271

15 (±)-2-[[5-[(Phenylmethyl)thio]-2-(4-piperidinylamino)thiazolo[4,5-d]pyrimidin-7-
yl]amino]-1-propanol

a) 7-Chloro-5-[(phenylmethyl)thio]-N-(4-piperidinyl)-thiazolo[4,5-d]pyrimidin-2-
amine

20

A solution of the product from Example 219 (0.3g) in tetrahydrofuran (2ml) containing 4-
amino-1-piperidinecarboxylic acid, 1,1-dimethylethyl ester (0.161g) and
N-ethyl-diisopropylamine (0.5 ml) was stirred for 16 hours before evaporating to dryness.
The residue was taken into dichloromethane (30ml) and trifluoroacetic acid (3ml) added.

25 The solution was stirred for 30 minutes then concentrated to give the title compound
(310mg).

MS (APCI) 392 (M+H⁺, 100%).

30 NMR δH (d₆-DMSO) 9.47 (1H, s), 8.64-8.48 (2H, s), 7.46-7.23 (5H, s), 4.41 (2H, s) 4.21
(1H, s), 3.34 (2H, m), 3.09 (2H, m), 2.18 (2H, m), 1.69 (2H, m).

b) (±)-2-[[5-[(Phenylmethyl)thio]-2-(4-piperidinylamino)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

5 Prepared by the method of Example 221, using the product of step a).

MS (APCI) 431 (M+H⁺, 100%).

Example 272

10 *N*-[2-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5 *d*]pyrimidin-2-yl]amino]ethyl]-acetamide

Prepared according to the method of Example 231 using the product of Example 219.

15 MS (APCI) 396, 394 (M+H⁺), 394 (100%).

Examples 273-276

Examples 273-276 were prepared by the method of Example 221 using the product of Example 272.

20

Example 273

(±)-*N*-[2-[[7-[[1-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-acetamide

25 MS (APCI) 447 (M+H⁺, 100%)

Examples 274

(±)-*N*-[2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-acetamide,

30

MS (APCI) 433 ($M+H^+$, 100%)

Examples 275

5 *N*-[2-[[7-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-acetamide

MS (APCI) 419 ($M+H^+$, 100%)

Example 276

10 *N*-[2-[[7-[(1*R*)-1-(Hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-acetamide,

MS (APCI) 475 ($M+H^+$, 100%)

15 Example 277

7-Chloro-5-[(phenylmethyl)thio]-*N*-[2-(2-thienyl)ethyl]-thiazolo[4,5-*d*]pyrimidin-2-amine

20 Prepared by the method of Example 231, using the product of Example 219 and 2-(2-thienyl)ethylamine.

MS (APCI), 420, 418 ($M+H^+$), 418 (100%).

NMR δ H (d_6 -DMSO) 7.45-7.32 (5H, m), 6.96 (2H, m), 4.40 (2H, s), 3.78 (2H, s), 3.16 (2H, t).

25

Examples 278-284

Examples 276 to 284 were prepared by the method of Example 221 using the product of Example 277.

Example 278

*N*⁷-(2-Methoxyethyl)-5-[(phenylmethyl)thio]-*N*²-[2-(2-thienyl)ethyl]thiazolo[4,5-*d*]pyrimidine-2,7-diamine

5 MS (APCI) 457 (M+H⁺, 100%).

Example 279

*N*⁷-(2-Ethoxyethyl)-5-[(phenylmethyl)thio]-*N*²-[2-(2-thienyl)ethyl]thiazolo[4,5-*d*]pyrimidine-2,7-diamine

10

MS (APCI) 471 (M+H⁺, 100%).

Example 280

*N*⁷-(2,2-Dimethylpropyl)-5-[(phenylmethyl)thio]-*N*²-[2-(2-thienyl)ethyl]thiazolo[4,5-*d*]pyrimidine-2,7-diamine

15

MS (APCI) 469 (M+H⁺, 100%).

Example 281

(2*R*)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol

20

MS (APCI) 499 (M+H⁺, 100%).

Example 282

(±)-1-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol

25

MS (APCI) 457 (M+H⁺, 100%).

30

Example 283

(±)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]- 1-butanol

5 MS (APCI) 471 (M+H⁺, 100%).

Example 284

(±)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]- 1-propanol

10

MS (APCI) 457 (M+H⁺, 100%).

Example 285

2-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-ethanol

15

Prepared by the method of Example 231, using the product of Example 219 and 2-aminoethanol.

MS (APCI) 355, 353 (M+H⁺), 353 (100%).

20

NMR δH (d₆-DMSO) 9.48 (1H, s), 7.45-7.30 (5H, m), 4.95 (1H, t), 4.40 (2H, s), 3.60 (4H, m).

Examples 286-287

Examples 286 to 287 were prepared by the method of Example 221 using the product of Example 285.

25

Example 286

(2*R*)-2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol

30

MS (APCI) 433 ($M+H^+$, 100%).

Example 287

(±)-*N,N*-Diethyl-1-[2-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
5 *d*]pyrimidin-7-yl]-3-piperidinecarboxamide

MS (APCI) 500 ($M+H^+$, 100%).

Example 288

10 3-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-propanol

Prepared by the method of Example 231, using the product of Example 219 and 3-aminopropanol.

15 MS (APCI) 369, 367 ($M+H^+$), 367 (100%).

NMR δ H (d_6 -DMSO) 9.36 (1H, s), 7.43-7.27 (5H, m), 4.57 (1H, t), 4.40 (2H, s), 3.49 (4H, m), 1.75 (2H, m).

Examples 289-291

20 Examples 289-291 were prepared by the method of Example 221 using the product of Example 288.

Example 289

(2*R*)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
25 *d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol

MS (APCI) 447 ($M+H^+$, 100%).

Example 290

(±)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol

5 MS (APCI) 419 (M+H⁺, 100%).

Example 291

(±)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

10

MS (APCI) 405 (M+H⁺, 100%)

Example 292

2-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-acetamide

15

Prepared by the method of Example 231, using the product of Example 219 and glycine hydrochloride.

MS (APCI) 368, 66 (M+H⁺), 366 (100%).

20

NMR δH (d₆-DMSO) 7.61 (1H, s), 7.45-7.24 (6H, m), 4.40 (2H, s), 4.14-4.12 (2H, m), 9.57 (1H, s).

Example 293

2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-acetamide

25

Prepared according to the method of Example 221 using the product of Example 292.

MS (APCI) 404 (M+H⁺, 100%).

30

Example 294**4-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]-3-azetidiny]-1-piperazinesulfonamide**

- 5 Prepared by the method of Example 231, using the product of Example 219 and 3-azetidiny-1-piperazinesulfonamide.

MS (APCI), 512, 514 (M+H⁺), 512 (100%).

NMR δH (d₆-DMSO) 7.69-7.22 (5H, m), 6.80 (2H, s), 4.40 (2H, s), 4.34-4.12 (4H, m),
10 3.56-3.50 (1H, m), 3.40 (4H, s), 3.00 (4H, s).

Example 295**4-[1-[7-[(4-Methylcyclohexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]-3-azetidiny]-1-piperazinesulfonamide,**

15

Prepared by the method of Example 221, using the product of Example 294.

MS (APCI) 588 (M+H⁺, 100%).

20

Example 296**7-Chloro-*N*-[[2-(4-morpholinyl)ethyl]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidin-2-amine**

25

Prepared by the method of Example 231, using the product of Example 219 and 2-(4-morpholinyl)ethylamine.

MS (APCI) 424, 422 (M+H⁺), 422 (100%).

NMR δH (d₆-DMSO) 9.34 (1H, s), 7.68-7.23 (5H, m), 4.40 (2H, s), 3.59-3.56 (6H, m),
2.54 (2H, t), 2.44-2.41 (4H, m).

30

Examples 297-300

Examples 297-300 were prepared according to the method of Example 221 using the product of Example 296.

5 Example 297

**3-[[2-[[2-(4-Morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-1-propanol**

MS (APCI) 460 (M+H⁺, 100%).

10

Example 298

**2-Methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-1-propanol**

15 MS (APCI) 464 (M+H⁺, 100%).

Example 299

**(±)-2-[[2-[[2-(4-Morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-
d]pyrimidin-7-yl]amino]-1-propanol**

20

MS (APCI) 460 (M+H⁺, 100%).

Example 300

**(2R)-4-Methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-
25 [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-pentanol**

MS (APCI) 502 (M+H⁺, 100%).

Examples 301-302

Examples 301-302 were prepared by the method of Example 12 using the product of Example 140.

5 Example 301

2-[[2-(3,4-Dihydroxyphenyl)ethyl]amino]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one

MS (APCI) 427 (M+H⁺, 100%).

10

Example 302

(±)-2-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one

15 MS (APCI) 349 (M+H⁺, 100%).

Pharmacological Data**Ligand Binding Assay**

20 [¹²⁵I]IL-8 (human, recombinant) was purchased from Amersham, U.K. with a specific activity of 2,000Ci/mmol. All other chemicals were of analytical grade. High levels of hrCXCR2 were expressed in HEK 293 cells (human embryo kidney 293 cells ECACC No. 85120602) (Lee *et al.* (1992) *J. Biol. Chem.* **267** pp16283-16291). hrCXCR2 cDNA was amplified and cloned from human neutrophil mRNA. The DNA was cloned into PCRScript
25 (Stratagene) and clones were identified using DNA. The coding sequence was sub-cloned into the eukaryotic expression vector RccMV (Invitrogen). Plasmid DNA was prepared using Quiagen Megaprep 2500 and transfected into HEK 293 cells using Lipofectamine reagent (Gibco BRL). Cells of the highest expressing clone were harvested in phosphate-buffered saline containing 0.2%(w/v) ethylenediaminetetraacetic acid (EDTA) and
30 centrifuged (200g, 5min.). The cell pellet was resuspended in ice cold homogenisation

buffer [10mM HEPES (pH 7.4), 1mM dithiothreitol, 1mM EDTA and a panel of protease inhibitors (1mM phenyl methyl sulphonyl fluoride, 2µg/ml soybean trypsin inhibitor, 3mM benzamidine, 0.5µg/ml leupeptin and 100µg/ml bacitracin)] and the cells left to swell for 10 minutes. The cell preparation was disrupted using a hand held glass mortar/PTFE pestle homogeniser and cell membranes harvested by centrifugation (45 minutes, 100,000g, 4°C). The membrane preparation was stored at -70°C in homogenisation buffer supplemented with Tyrode's salt solution (137mM NaCl, 2.7mM KCl, 0.4mM NaH₂PO₄), 0.1%(w/v) gelatin and 10%(v/v) glycerol.

All assays were performed in a 96-well MultiScreen 0.45µm filtration plates (Millipore, U.K.). Each assay contained ~50pM [¹²⁵I]IL-8 and membranes (equivalent to ~200,000 cells) in assay buffer [Tyrode's salt solution supplemented with 10mM HEPES (pH 7.4), 1.8mM CaCl₂, 1mM MgCl₂, 0.125mg/ml bacitracin and 0.1%(w/v) gelatin]. In addition, a compound of formula (I) according to the Examples was pre-dissolved in DMSO and added to reach a final concentration of 1%(v/v) DMSO. The assay was initiated with the addition of membranes and after 1.5 hours at room temperature the membranes were harvested by filtration using a Millipore MultiScreen vacuum manifold and washed twice with assay buffer (without bacitracin). The backing plate was removed from the MultiScreen plate assembly, the filters dried at room temperature, punched out and then counted on a Cobra γ-counter.

The compounds of formula (I) according to the Examples were found to have IC₅₀ values of less than (<) 10µM.

Intracellular Calcium Mobilisation Assay

Human neutrophils were prepared from EDTA-treated peripheral blood, as previously described (Baly *et al.* (1997) *Methods in Enzymology* 287 pp70-72), in storage buffer [Tyrode's salt solution (137mM NaCl, 2.7mM KCl, 0.4mM NaH₂PO₄) supplemented with 5.7mM glucose and 10mM HEPES (pH 7.4)].


The chemokine GRO α (human, recombinant) was purchased from R&D Systems (Abingdon, U.K.). All other chemicals were of analytical grade. Changes in intracellular free calcium were measured fluorometrically by loading neutrophils with the calcium sensitive fluorescent dye, fluo-3, as described previously (Merritt *et al.* (1990) *Biochem. J.* 5 269, pp513-519). Cells were loaded for 1 hour at 37°C in loading buffer (storage buffer with 0.1%(w/v) gelatin) containing 5 μ M fluo-3 AM ester, washed with loading buffer and then resuspended in Tyrode's salt solution supplemented with 5.7mM glucose, 0.1%(w/v) bovine serum albumin (BSA), 1.8mM CaCl₂ and 1mM MgCl₂. The cells were pipetted into black walled, clear bottom, 96 well micro plates (Costar, Boston, U.S.A.) and 10 centrifuged (200g, 5 minutes, room temperature).

A compound of formula (I) according to the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1%(v/v) DMSO. Assays were initiated by the addition of an A₅₀ concentration of GRO α and the transient increase in fluo-3 fluorescence (λ_{Ex} 15 =490nm and λ_{Em} = 520nm) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.).


The compounds of formula (I) according to the Examples were tested and found to be antagonists of the CXCR2 receptor in human neutrophils.

CLAIMS

1. A compound of general formula



- 5 wherein R^1 represents a hydrogen atom, or a group $-NR^3R^4$;
 R^3 and R^4 each independently represent a hydrogen atom, or a 4-piperidiny, C_3 - C_6
 cycloalkyl or C_1 - C_8 alkyl group, which latter two groups may be optionally substituted by
 one or more substituent groups independently selected from halogen atoms and $-NR^5R^6$,
 $-CONR^5R^6$, $-OR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$,
 10 morpholinyl, C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, tetrahydrofuranyl and aryl groups, wherein
 an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or
 indolyl group, each of which may be optionally substituted by one or more substituents
 independently selected from halogen atoms and cyano, nitro, $-NR^5R^6$, $-CONR^5R^6$, $-$
 OR^7 , $-NR^8COR^9$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_1 - C_6 alkyl and trifluoromethyl groups,
 15 or R^3 and R^4 together with the nitrogen atom to which they are attached form a 4- to
 7-membered saturated heterocyclic ring system, which ring system may be optionally
 substituted by one or more substituent groups independently selected from



- $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-COOR^{10}$, $-NR^8COR^9$, and C_1 - C_6 alkyl optionally
 20 substituted by one or more substituents independently selected from halogen atoms and
 $-NR^{11}R^{12}$ and $-OR^7$ groups;
 X represents a group $-OH$ or $-NR^{13}R^{14}$;

R^{13} and R^{14} each independently represent a hydrogen atom, a 4-piperidinyl group optionally substituted by a C_1 - C_4 alkylphenyl substituent group, or a C_3 - C_7 carbocyclic, C_1 - C_8 alkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl group, which latter four groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, morpholinyl, C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-NR^8COR^9$, $-SO_2NR^5R^6$, $NR^8SO_2R^9$, C_1 - C_6 alkyl and trifluoromethyl groups, or R^{13} and R^{14} together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-COOR^7$, $-NR^8COR^9$, and C_1 - C_6 alkyl optionally substituted by one or more substituents independently selected from halogen atoms and phenyl, $-NR^{11}R^{12}$ and $-OR^7$ groups;

R^2 represents a C_1 - C_6 alkyl or C_2 - C_6 alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group may itself be optionally substituted by one or more substituents independently selected from halogen atoms and nitro, C_1 - C_6 alkyl, trifluoromethyl, $-OR^7$, $-C(O)R^7$, $-SR^{10}$, $-NR^{15}R^{16}$ and phenyl groups;

R^5 and R^6 each independently represent a hydrogen atom or a C_1 - C_6 alkyl or phenyl group, each of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, $-OR^{17}$ and $-NR^{15}R^{16}$, or R^5 and R^6 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system optionally comprising a further heteroatom selected from oxygen and nitrogen atoms, which ring system may be optionally substituted by one or more substituent groups independently selected from phenyl, $-OR^{17}$, $-COOR^{17}$, $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SONR^{15}R^{16}$, and C_1 - C_6 alkyl

optionally substituted by one or more substituents independently selected from halogen atoms and $-\text{NR}^{15}\text{R}^{16}$ and $-\text{OR}^{17}$ groups;

R^7 and R^9 each independently represent a hydrogen atom or a C_1 - C_6 alkyl or phenyl group, each of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, $-\text{OR}^{17}$ and $-\text{NR}^{15}\text{R}^{16}$; and each of R^8 , R^{10} , R^{11} , R^{12} , R^{15} , R^{16} and R^{17} independently represents a hydrogen atom or a C_1 - C_6 alkyl or phenyl group; with the proviso that when R^1 and X both represent $-\text{NH}_2$, then R^2 does not represent a methyl group;

or a pharmaceutically acceptable salt or solvate thereof.

10

2. A compound according to claim 1, wherein R^1 represents a group $-\text{NR}^3\text{R}^4$.

3. A compound according to claim 1 or claim 2, wherein R^3 and R^4 each independently represent a hydrogen atom, or a 4-piperidinyl, C_3 - C_6 cycloalkyl or C_1 - C_6 alkyl group, which latter two groups may be optionally substituted by one, two, three or four substituent groups independently selected from halogen atoms and $-\text{NR}^5\text{R}^6$, $-\text{CONR}^5\text{R}^6$, $-\text{OR}^7$, $-\text{COOR}^7$, $-\text{NR}^8\text{COR}^9$, $-\text{SR}^{10}$, $-\text{SO}_2\text{R}^{10}$, $-\text{SO}_2\text{NR}^5\text{R}^6$, $-\text{NR}^8\text{SO}_2\text{R}^9$, morpholinyl, C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, tetrahydrofuranyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one, two, three or four substituents independently selected from halogen atoms and cyano, nitro, $-\text{NR}^5\text{R}^6$, $-\text{CONR}^5\text{R}^6$, $-\text{OR}^7$, $-\text{NR}^8\text{COR}^9$, $-\text{SO}_2\text{NR}^5\text{R}^6$, $-\text{NR}^8\text{SO}_2\text{R}^9$, C_1 - C_4 alkyl and trifluoromethyl groups.

20

4. A compound according to any one of claims 1 to 3, wherein R^2 represents a C_1 - C_6 alkyl or C_2 - C_6 alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group may itself be optionally substituted by one, two, three or four substituents independently selected from halogen atoms and nitro, C_1 - C_4 alkyl, trifluoromethyl, $-\text{OR}^7$, $-\text{C}(\text{O})\text{R}^7$, $-\text{SR}^{10}$, $-\text{NR}^{15}\text{R}^{16}$ and phenyl.

25

5. A compound according to any one of the preceding claims, wherein X represents $-NR^{13}R^{14}$ and R^{13} and R^{14} each independently represent a hydrogen atom, a 4-piperidinyl group optionally substituted by a C_1 - C_4 alkylphenyl substituent group, or a C_3 - C_7 carbocyclic, C_1 - C_6 alkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl group, which latter four groups may be optionally substituted by one, two, three or four substituent groups independently selected from halogen atoms and $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, morpholinyl, C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one, two, three or four substituents independently selected from halogen atoms and cyano, nitro, $-NR^5R^6$, $-CONR^5R^6$, $-OR^7$, $-NR^8COR^9$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_1 - C_4 alkyl and trifluoromethyl groups.
6. A compound according to claim 1 being selected from:
- (2*R*)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
 (5*S*)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
 2-Amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 5-[[3-Phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 (±)-2-[[2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
 2-[[2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethanol,
 5-(Pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-[[3-(Dimethylamino)propyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-[[2-(Diethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-[[2-(Dimethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-[(3-Hydroxypropyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-[[2-(Acetylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 (±)-2-[(2,3-Dihydroxypropyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,

- 2-[[2-(4-Morpholinyl)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-[(2-Methoxyethyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-[(1-Methylethyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-(Cyclopropylamino)-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 5 (±)-2-[(2-Hydroxypropyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-[(2-Hydroxy-2-methylpropyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 2-[(2-Hydroxyethyl)amino]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 (2*S*,3*R*)-3-Hydroxy-2-[(7-oxo-5-(pentylthio)-4*H*-thiazolo[4,5-*d*]pyrimidin-2-yl)-
 10 amino)butanamide,
*N*⁷-[3-(Dimethylamino)propyl]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
*N*⁷-[2-(Diethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
*N*⁷-[2-(Dimethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
 3-[(2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl)amino]-1-propanol,
 15 *N*⁷-Cyclohexyl-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
 (±)-3-[(2-Amino-5-((phenylmethyl)thio)thiazolo[4,5-*d*]pyrimidin-7-yl)amino]-1,2-
 propanediol,
*N*⁷-(2-Methoxyethyl)-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
 5-(Pentylthio)-*N*⁷-propylthiazolo[4,5-*d*]pyrimidine-2,7-diamine,
 20 *N*⁷-Cyclopentyl-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
*N*⁷-Cyclopropyl-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
*N*⁷-(2-Methylpropyl)-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
 (±)-1-[(2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl)amino]-2-propanol,
 (exo)-*N*⁷-Bicyclo[2.2.1]hept-2-yl-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
 25 2-[2-[(2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl)amino]ethoxy]ethanol,
 (±)-*N*⁷-(2-Methylbutyl)-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
 1-[[2-Amino-5-(pentylthio)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-2-propanol,
*N*⁷-[(2-Aminophenyl)methyl]-5-(pentylthio)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
 2-Amino-5-[(2-phenoxyethyl)thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
 30 (*E*)-2-Amino-5-[(3-phenyl-2-propenyl)thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,

- 2-Amino-5-[[3-[2,4-bis(1,1-dimethylethyl)phenoxy]propyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(4-trifluoromethyl)phenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(3,5-dichlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 5 2-Amino-5-[[[(2,4-dichlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(3,4-dichlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(3,5-dibromophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(2-nitrophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 10 2-Amino-5-[[[(2-iodophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(3-chlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(2-chlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(4-chloro-2-nitrophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(3-chloro-4-methoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 15 2-Amino-5-[[[(2,3-dichlorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(3,5-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(2,4-bis(trifluoromethyl)phenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(2-bromophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 20 2-Amino-5-[[[(2,3,4-trifluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(3-bromophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 2-Amino-5-[[[(2-fluoro-3-methylphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
- 3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2,2-dimethyl-1-propanol,
- 25 (±)-α-[[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]methyl]benzenemethanol,
- (*R*)-β-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]benzenepropanol,
- 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethanol,

- (2*R*)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]4-methylpentanol,
- (±)-1-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol,
- (±)-β-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-chlorobenzenepropanol,
- 5 (±)-3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,2-propanediol,
- 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]propylamino]ethanol,
- (±)-1-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-pyrrolidinol,
- 10 (±)-1-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinol,
- 1-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-piperidinol,
- 3-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2,2-dimethyl-1-propanol,
- (±)-2-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-
- 15 1-butanol,
- (±)-α-[[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-amino]methyl]benzenemethanol,
- 4-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- 20 6-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-hexanol,
- 4-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-amino]cyclohexanol,
- (*R*)-β-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-
- 25 amino]benzenepropanol,
- (±)-2-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 2-[[2-Amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-amino]ethanol,

- (2R)-2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-amino]-4-methylpentanol,
- (±)-1-Amino-3-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol,
- 5 (±)-1-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol,
- 2-[[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]methyl]-2-ethyl-1,3-propanediol,
- (±)-β-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-
- 10 4-chlorobenzenepropanol,
- (±)-3-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,2-propanediol,
- 2-[[2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethyl]amino]ethanol,
- 15 3-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- (±)-α-[[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]methyl]-3,4-dichlorobenzenepropanol,
- 1-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-
- 20 methyl-2-propanol,
- 2-[2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethoxy]ethanol,
- 5-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol,
- 25 (2S)-2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-(methylthio)-1-butanol,
- 2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]butylamino]ethanol,
- 2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-
- 30 yl]propylamino]ethanol,

- 2,2'-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]imino]bisethanol,
- 2-[[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-(2-hydroxyethyl)amino]methyl]phenol,
- 5 3-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-(2-hydroxyethyl)amino]-1-propanol,
- (±)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-pyrrolidinol,
- (*trans*)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-hydroxy-*L*-proline phenylmethyl ester,
- 10 (±)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinemethanol,
- (±)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinol,
- 15 (2*S*)-1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-2-pyrrolidinemethanol,
- 1-[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-piperidinol,
- (2*R*)-2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- 20 (2*S*)-2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- (2*R*)-2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- 25 2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,3-propanediol,
- 2-[[2-Amino-5-[[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 30

- 1-[[2-Amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-2-propanol,
5-[[2,3-Difluorophenyl)methyl]thio]-*N*⁷-(2-fluoroethyl)thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
5 (1*R*-*trans*) 2-[[2-Amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-cyclopentanol,
(1*S*-*trans*) 2-[[2-Amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-cyclopentanol,
2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-
10 propanol,
2-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
2-[[2-[[5-[[2,3-Difluorophenyl)methyl]thio]-2-[(phenylmethyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
15 5-[[2,3-Difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,
(±)-2-[[2-Amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
(1*S*,2*S*)-2-[[2-Amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-cyclohexanol,
20 (±)-2-[[2-Amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
2-[[2-Amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-ethanol,
(2*R*)-2-[[2-Amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-
25 yl]amino]-4-methyl-1-pentanol,
(±)-1-[[2-Amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol,
2-[[2-Amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1,3-propanediol,

- 1-[[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]methyl]-cyclohexanol,
(2*R*)-2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
5 2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-(2-aminoethyl)amino]-1-ethanol,
2-[2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]ethoxy]-1-ethanol,
(α *S*)- α -[(1*R*)-1-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-
10 7-yl]methylamino]ethyl]-benzenemethanol,
1-[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-piperidinol,
5-[[[(2,3-Difluorophenyl)methyl]thio]-*N*⁷-ethyl-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
5-[[[(2,3-Difluorophenyl)methyl]thio]-*N*⁷-(2-propenyl)-thiazolo[4,5-*d*]pyrimidine-2,7-
15 diamine,
(1*S*,2*S*)-2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-phenyl-1,3-propanediol,
2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,3-propanediol,
20 2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-ethanol,
(\pm)-5-[[[(2,3-Difluorophenyl)methyl]thio]-*N*⁷-(2-methoxy-1-methylethyl)-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
*N*⁷-Cyclopropyl-5-[[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-*d*]pyrimidine-2,7-
25 diamine,
(\pm)-2-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
4-[[2-Amino-5-[[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,

- 5-[[[(2,3-Difluorophenyl)methyl]thio]-*N*⁷-[2-(1*H*-imidazol-4-yl)ethyl]-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
(±)-*N*-[5-[[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-*d*]pyrimidin-2-yl]-serine, methyl ester,
- 5 2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(1-methylethyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-(ethylamino)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(1*H*-indol-3-yl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 10 2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(1,2-diphenylethyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 15 2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(2,2,2-trifluoroethyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(3,4,5-trimethoxyphenyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 20 2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(1,1-dimethylethyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(4-methylcyclohexyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 25 2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-acetamide,
2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

2-[[2-(Cyclopropylamino)-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

5 (±)-2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-pentanol,

2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-hydroxyethoxy)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
N-[5-[[[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-*d*]pyrimidin-2-yl]-DL-serine, methyl ester,

10 5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(1-methylethyl)amino]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,

5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(1*H*-indol-3-yl)ethyl]amino]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,

15 2-[[5-[[[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-acetamide,

2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,

5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,

20 5-[[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-hydroxyethoxy)ethyl]amino]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,

2-[[2-(Cyclohexylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

25 2-[[2-[(1,1-Dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

N-[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]-DL-alanine, methyl ester,

4-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-cyclohexanol,

30

- 2-Methyl-2-[[2-[(4-phenylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 5 2-Methyl-2-[[2-[(1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- N*-[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]-L-valine, ethyl ester,
- 10 (2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-4-methyl-pentanamide,
- 2-Methyl-2-[[2-[(2-phenylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 15 2-[[2-[[4-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 2-[[2-[(2-Fluoroethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 20 2-Methyl-2-[[2-[[3-nitrophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- (α *R*)- α -[(1*S*)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-benzenemethanol,
- 25 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[3,4,5-trimethoxyphenyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 2-Methyl-2-[[2-[(1*R*-trans)-(2-phenylcyclopropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 2-[[2-[[2-(1*H*-Indol-3-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 30

- 2-[[2-[(1,1-Dimethylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- (±)-2-Methyl-2-[[2-[(1-methylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 5 (±)-2-Methyl-2-[[2-[(1-methylhexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 2-[[2-[(2-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1,3-propanediol,
- 10 2-[[2-[[2-(Ethylthio)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- (2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-3,3-dimethyl-1-butanol,
- 15 (α*S*)-α-[(1*R*)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-2-methoxyethyl]-benzenemethanol,
- 2-[[2-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 20 2-[[2-[[[3-Fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- (±)-2-Methyl-2-[[2-[(1-methylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 2-[[2-[[[4-Methoxyphenyl]methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 25 2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
- 2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

- 2-[[2-[(Diphenylmethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
(2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-butanol,
5 2-[[2-[(2,2-Diethoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
4-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-butanol,
(1*S*,2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-cyclohexanol,
10 (±)-2-[[2-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,
15 (±)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-pentanol,
2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-acetamide,
(±)-2-[[2-[[1-(4-Fluorophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-propanol,
20 (1*R*,2*S*)-2-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-cyclohexanol,
(α*S*)-α-[(1*R*)-1-[[7-[(2-Hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-benzenemethanol,
25 (±)-2-[[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
(2*R*)-4-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol,
N-[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-L-serine, ethyl
30 ester,

- (±)-2-[[5-[(Phenylmethyl)thio]-2-[[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- (±)-2-[[5-[(Phenylmethyl)thio]-2-[[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 5 (2*R*)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol,
- N*-[5-[(Phenylmethyl)thio]-2-[[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]-L-serine, ethyl ester,
- (±)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 10 (±)-4-[2-[[7-[[1-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,
- (±)-4-[2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,
- 15 4-[2-[[7-[[1-(1*R*)-1-(Hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,
- (±)-4-[2-[[7-[(2-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide,
- N*⁷-Ethyl-*N*²-[2-(1*H*-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidine-
- 20 2,7-diamine,
- N*²-[2-(1*H*-Imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]-*N*⁷-(3-pyridinylmethyl)-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
- (±)-2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- 25 (±)-2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- (2*R*)-2-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
- (±)-1-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-propanol,
- 30

5-[[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol,

1-[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-(phenylmethyl)-4-piperidinol,

5 (±)-1-[2-[[2-(1*H*-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinecarboxamide,

2-[Ethyl[2-[[2-(1*H*-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-ethanol,

10 *N*²-[2-(1*H*-Imidazol-4-yl)ethyl]-*N*⁷,*N*⁷-dimethyl-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,

*N*⁷-[2-(Diethylamino)ethyl]-*N*⁷-ethyl-*N*²-[2-(1*H*-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,

*N*²-(2-Phenoxyethyl)-5-[(phenylmethyl)thio]-*N*⁷-(3-pyridinylmethyl)-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,

15 *N*²-(2-Phenoxyethyl)-*N*⁷-[1-(phenylmethyl)-4-piperidinyl]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidine-2,7-diamine,

2-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

20 (±)-2-[[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

(±)-4-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol,

1-[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-4-(phenylmethyl)-4-piperidinol,

25 2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,

2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

30 (2*R*)-2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,

N-[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-L-serine, ethyl ester,

(2*R*)-2-[[2-[[1-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,

5 *N*-[2-[[1-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-L-serine, ethyl ester,

(±)-2-[[7-[Cyclohexyl(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-1-pentanol,

2-[[2-[[7-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethoxy]-1-ethanol,

10 2-[[2-[[7-[(1-Methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethoxy]-1-ethanol,

(±)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,

15 2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol,

(2*R*)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,

2-[[Cyclohexyl-[2-[[2-(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-ethanol,

20 (±)-2-[[5-[(Phenylmethyl)thio]-2-(4-piperidinylamino)thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

(±)-*N*-[2-[[7-[[1-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-acetamide,

25 (±)-*N*-[2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-acetamide,

N-[2-[[7-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-acetamide,

N-[2-[[7-[(1*R*)-1-(Hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]ethyl]-acetamide,

30

- N*⁷-(2-Methoxyethyl)-5-[(phenylmethyl)thio]-*N*²-[2-(2-thienyl)ethyl]thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
- N*⁷-(2-Ethoxyethyl)-5-[(phenylmethyl)thio]-*N*²-[2-(2-thienyl)ethyl]thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
- 5 *N*⁷-(2,2-Dimethylpropyl)-5-[(phenylmethyl)thio]-*N*²-[2-(2-thienyl)ethyl]thiazolo[4,5-*d*]pyrimidine-2,7-diamine,
- (2*R*)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol,
- (±)-1-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]- 2-propanol,
- 10 (±)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]- 1-butanol,
- (±)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 15 (2*R*)-2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
- (±)-*N,N*-Diethyl-1-[2-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]-3-piperidinecarboxamide,
- (2*R*)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methyl-1-pentanol,
- 20 (±)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-butanol,
- (±)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 25 2-[[7-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]amino]-acetamide,
- 4-[1-[7-[(4-Methylcyclohexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-yl]-3-azetidiny]-1-piperazinesulfonamide,
- 3-[[2-[[2-(4-Morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,
- 30

2-Methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

(±)-2-[[2-[[2-(4-Morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol,

5 (2*R*)-4-Methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-pentanol,


2-[[2-(3,4-Dihydroxyphenyl)ethyl]amino]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one,

(±)-2-[(2-Hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]-thiazolo[4,5-*d*]pyrimidin-
10 7(4*H*)-one,

and their pharmaceutically acceptable salts and solvates.


7. A process for the preparation of a compound of formula (I) as defined in claim 1 which comprises:

15 (a) when X represents -OH and R¹ is NH₂, heating a compound of general formula



wherein R² is as defined in formula (I); or


(b) when X represents -OH and R¹ is NH₂, reacting a compound of formula



20 with a compound of general formula (IV), R² - L¹, wherein L¹ represents a leaving group and R² is as defined in formula (I); or


(c) when X represents -OH or -NR¹³R¹⁴ and R¹ is a hydrogen atom, reacting a corresponding compound of formula (I) in which R¹ is NH₂, with a diazotizing agent; or

(d) when X represents -OH and R¹ is a group -NR³R⁴, reacting a compound of general
25 formula




wherein L^2 represents a leaving group and R^2 is as defined in formula (I), with a compound of general formula (VI), R^3R^4NH , wherein R^3 and R^4 are as defined in formula (I); or

- (e) when X represents $-NR^{13}R^{14}$ and R^1 represents $-NR^3R^4$, reacting a compound of
 5 general formula



wherein L^3 represents a leaving group and R^2 , R^3 and R^4 are as defined in formula (I), with a compound of general formula (VIII), $NHR^{13}R^{14}$, wherein R^{13} and R^{14} are as defined in formula (I); or

- (f) when X represents $-NR^{13}R^{14}$ and R^1 represents $-NR^3R^4$, reacting a compound of
 10 general formula



- wherein L^4 is a leaving group, L^5 is a leaving group and R^2 is as defined in formula (I), initially with a compound of formula (VI) as defined in (d) above followed by reaction with
 15 a compound of formula (VIII) as defined in (e) above;

and optionally after (a), (b), (c), (d), (e) or (f) forming a pharmaceutically acceptable salt or solvate of the compound of formula (I).

- 20 8. An intermediate compound of formula (V) as defined in claim 7.

9. An intermediate compound of formula (VII) as defined in claim 7.

10. An intermediate compound of formula (IX) as defined in claim 7.
11. A pharmaceutical composition comprising a compound of formula (I), or a
5 pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6
in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
12. A process for the preparation of a pharmaceutical composition as claimed in claim 11
which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt
10 or solvate thereof, as claimed in any one of claims 1 to 6 with a pharmaceutically
acceptable adjuvant, diluent or carrier.
13. A compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as
claimed in any one of claims 1 to 6 for use in therapy.
- 15 14. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate
thereof, as claimed in any one of claims 1 to 6 in the manufacture of a medicament for use
in therapy.
- 20 15. A method of treating a chemokine mediated disease wherein the chemokine binds to a
CXCR2 receptor, which comprises administering to a patient a therapeutically effective
amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate
thereof, as claimed in any one of claims 1 to 6.
- 25 16. A method of treating an inflammatory disease in a patient suffering from, or at risk of,
said disease, which comprises administering to the patient a therapeutically effective
amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate
thereof, as claimed in any one of claims 1 to 6.
- 30 17. A method according to claim 16, wherein the disease is psoriasis.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/01333

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07D 513/04, A61K 31/519, A61K 31/426, A61P 17/06, A61P 29/00
 // (C07D 513/04, 277:00, 239:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07D, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| A | J. Amer. Chem. Soc., Volume 73, Sept 1951, Allison Maggiolo et al, "Studies on Condensed Pyrimidine Systems. VI. Some 2-Aminothiazolo (4, 5-d)-pyrimidines" page 4226 - page 4228; page 4227 -- | 1-17 |
| A | J. Chem. Soc., 1970, J.A. Baker et al, "Synthesis of Derivatives of Thiazolo(4,5-d) pyrimidine. Part II"; pge 2478 - page 2484, page 2484, left column, fourth paragraph -- | 1-10 |
| A | STN International, File CAPLUS, CAPLUS accession no. 1996:243961, Document no. 125:10744, Gewald, K. et al: "New synthesis of substituted 4-aminoquinazolines and their hetero analogs"; J. Prakt. Chem./Chem.-Ztg. (1996), 338(3), 206-13 -- | 1-10 |

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

8 November 1999

Date of mailing of the international search report

13 -12- 1999

Name and mailing address of the ISA/
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer

Gerd Strandell/EÖ
 Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/01333

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| A | STN International, File CAPLUS, CAPLUS accession no. 1990:235252, Document no. 112:235252, Ahluwalia, V.K. et al: "One-step synthesis of thiazolo(4,5-d)pyrimidines"; Indian J. Chem., Sect. B (1989), 28B(11), 964-5 -- | 1-10 |
| A | STN International, File CAPLUS, CAPLUS accession no. 1990:158124, Document no. 112:158124, Pawar, R.A. et al: "Studies on the Vilsmeier-Haack reaction. A versatile new synthesis of 4-chloro-2-phenylaminothiazole-5-carboxaldehyde and related fused heterocyclic compounds and heterocyclic Schiff's bases"; Indian J. Chem., Indian J. Chem., Sect. B (1989), 28B(10), 866-7 -- | 1-17 |
| A | US 2772164 A (CHARLES F.H. ALLEN ET AL), 27 November 1956 (27.11.56), column 1, line 49 - column 2, line 10; column 4, line 71 - column 5, line 6, the claims -- | 1-10 |
| A | Chem. Pharm. Bull., Volume 6, 1958, Torizo Takahashi et al, "Studies on Pyrimidine Derivatives. I. Synthesis of Thiazolo (5, 4-d)pyrimidines and Related Compounds.(1).", page 334 - page 338, page 336(XI,XII); page 334 -- ----- | 1-17 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT SE99/01333

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **15-17**
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE99/01333

Claims 15-17 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

Information on patent family members

28/09/99

International application No.

PCT/SE 99/01333

Form PCT/ISA/210 (patent family annex) (July 1992)